Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
07/2011 | Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions July category listing 07/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/28/2011 > patent applications in patent subcategories. category listing

20110183885 - Neo-tryptophan: Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75,... Agent: Mayo Foundation For Medical Education And Research

20110183884 - Pan-antiviral peptides for protein kinase inhibition: A method of inhibiting protein kinases by administering polypeptides derived from alpha-neurotoxin, and inhibiting protein kinases. Diseases treated thereby include cancer, influenza, Tourette's syndrome, pain, and neurological deficits.... Agent:

20110183886 - Melanocortin receptor ligands: m

20110183887 - Methods and compositions for the reduction of neutrophil influx and the treatment of bronchopulmonary displasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly,... Agent: Clarassance, Inc.

20110183888 - Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various... Agent:

20110183889 - Salicylanilide modified peptides for use as oral therapeutics: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.... Agent: The Regents Of The University Of California

20110183890 - Methods for modulating angiogenesis via dystrophin dp71: The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110183891 - Methods and compositions for inhibiting fungal infection and disease: The present invention describes a previously unknown interaction between secreted aspartic proteases (SAPs), including SAPs 4-6 of Candida albicans, and integrins on host cells. The SAPs secure entry into the host cell through RGD-like binding motifs and subsequently induce apoptosis, thereby clearing the way for systemic infection. The invention thus... Agent:

20110183892 - Methods for the treatment of viral conditions: The invention is directed to a method of stimulating PRF in a viral cell by administering an aminoglycoside antibiotic to said cell. In another embodiment, the invention is directed to a method of inhibiting viral replication by administering an aminoglycoside antibiotic to a viral cell. The invention is also directed... Agent:

20110183893 - Non-natural mic proteins: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with... Agent: Avidbiotics Corporation

20110183894 - Antiviral activity of the protein scytovirin and methods of use: The present invention features methods of treating or preventing a viral infection in a subject, methods of inhibiting a virus in a biological sample, and methods of treating or preventing a viral infection caused by a virus in or on the skin or mucus membrane. The instant invention describes novel... Agent:

20110183895 - Polyheterocyclic compounds highly potent as hcv inhibitors: e

20110183896 - Enhancement of bacillus thuringiensis cry protein toxicities to coleopterans, and novel insect cadherin fragments: The subject invention relates in part to the discovery that a fragment from a cadherin of the western corn rootworm enhances Cry3 toxicity to larvae of naturally susceptible species. The subject invention also relates in part to the discovery that a cadherin fragment from a beetle enhances Cry3Aa and Cry3Bb... Agent: The University Of Georgia Research Foundation, Inc

20110183897 - Variant activin receptor polypeptides: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and... Agent: Amgen Inc.

20110183898 - Compositions for delivering peptide yy and pyy ag0nists: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The... Agent: Emisphere Technologies Inc.

20110183899 - Methods and compositions for the treatment of obesity: The invention relates to methods and compositions for the treatment of obesity. The methods and compositions relate to the use of an agent that reduces or prevents endoplasmic reticulum stress in conjunction with leptin.... Agent: Children's Medical Center Corporation

20110183900 - High caloric enteral formulations: Compositions and methods relating to high caloric enteral formulations are disclosed herein. The invention provides a dietary composition comprising hydrolyzed soy protein and having a low viscosity and acceptable shelf life. Methods of using the dietary compositions of the invention are also disclosed.... Agent: Solae, LLC

20110183901 - Superior control of blood glucose in diabetes treatment: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration.... Agent: Mannkind Corporation

20110183902 - Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition: Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.... Agent: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.

20110183903 - Use of pegylated igf-i variants for the treatment of neuromuscular disorders: The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where... Agent:

20110183904 - Methods and compositions for altering behavior associated with autism spectrum disorder: The present invention discloses methods for the diagnosis and treatment of autism. The diagnostic tools provided use analysis of levels of G-protein expression, oxytocin, and vasopressin. Treatment for autism spectrum disorder and symptoms of autism spectrum disorder, especially repetitive behavior, is also provided.... Agent: The Children's Mercy Hospital

20110183905 - Pharmaceutical compositions: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.... Agent:

20110183906 - Factor ix conjugates with extended half-lives: The present invention relates to conjugates of Factor IX that have been modified to include a biocompatible polymer moiety. The Factor IX conjugates are substantially free of contamination by Factor IXa. The Factor IX conjugates have improved pharmacokinetic properties, such as increased half-life, which results in dose sparing and less... Agent: Celtic Pharma Peg Ltd.

20110183907 - Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded... Agent:

20110183908 - Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions: The present invention relates to the use of Yersinia outer protein M (YopM), a YopM fragment, or a YopM variant, which is capable of autopenetrating the cell membrane and of integrating into the cell cytosol without the requirement of additional factors for delivering a cargo molecule across the membrane to... Agent:

20110183909 - Treatment of mood and anxiety disorders: The invention relates to a selective inhibitor of Elk-1 or MSK-1 activation for use in the prevention and/or treatment of mood and anxiety disorders.... Agent: Universite Pierre Et Marie Curie

20110183910 - Biglycan and related therapeutics and methods of use: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those... Agent: Brown University Research Foundation

20110183911 - Method for improving neurotransmission failure using a novel agent: A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for... Agent: Juridical Foundation The Chemo-sero-therapeutic Research Insttitute

20110183912 - Agent for promoting neuronal differentiation and method therefor: An agent for promoting neuronal differentiation of a neural stem/progenitor cell includes an inhibitor of function of a COUP-TFI protein and/or a COUP-TFII protein. To promote neuronal differentiation of a neural stem/progenitor cell, the agent is administered to the neural stem/progenitor cell to inhibit function of a COUP-TFI protein and/or... Agent: Keio University

20110183913 - Novel lipid dipeptide and gel: There is provided a gelator that is capable of forming a gel by an extremely small amount of addition in a wide pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility, and biodegradability. A gelator comprising: a lipid peptide of Formula (1) wherein R1... Agent: Nissan Chemical Industries, Ltd.

20110183914 - Personal care compositions: Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen.... Agent:

20110183916 - Apo-2 ligand: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand... Agent: Genentech, Inc.

20110183917 - P53 activator peptides: The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical... Agent:

20110183915 - Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component.... Agent:

20110183918 - Method of treating leukemia using rcie prolamin: The present invention relates to a method of treating leukemia using rice prolamin, and a pharmaceutical composition for treating leukemia, comprising an effective amount of rice prolamin together with one or more pharmaceutically acceptable carriers or excipients. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear... Agent: Mackay Memorial Hospital

20110183919 - Novel dipeptidyl peptidase iv (dp-iv) compounds: e

20110183920 - Modified il-4 mutein receptor antagonists: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals... Agent: Aerovance, Inc.

20110183921 - Peptides capable of modulating the function of tirc7: Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided.... Agent: Jojomed Gmbh

20110183922 - Peptides that enhance acetylcholinesterase expression: The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides.... Agent: University Of Miami

20110183923 - Peptide antagonists of zonulin and methods for use of the same: Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.... Agent: University Of Maryland, Baltimore

20110183924 - Methods and systems for annotating biomolecular sequences: A method of annotating biomolecular sequences. The method comprises (a) computationally clustering the biomolecular sequences according to a progressive homology range, to thereby generate a plurality of clusters each being of a predetermined homology of the homology range; and (b) assigning at least one ontology to each cluster of the... Agent: Compugen Ltd.

20110183925 - Anti-inflammatory peptide: Provided is an anti-inflammatory composition which has a high efficacy, causes no concern about side effects, is easy to ingest, and can also be administered for a long period of time because of its low cost and high safety. The present invention relates to a peptide comprising an amino acid... Agent: Nisshin Pharma Inc.

20110183927 - Compositions comprising sugar-cysteine products: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.... Agent: Max International, LLC

20110183926 - Treatment using continuous low dose application of sugar analogs: Methods and uses of low dosage nonmetabolizable D-glucose analogs and mannose analogs such as 2-deoxy-D-glucose, 5-thio-D-glucose, 2-fluoro-2-deoxy-D-glucose, 2-chloro-2-deoxy-D-glucose, 2-bromo-2-deoxy-D-glueose, 2-deoxy-2-fluoro-mannose, 2-deoxy-2-chloro-mannose, 3-deoxy mannose, 4-deoxy mannose, and 2,3 didioxy mannose, for the treatment of tumors.... Agent: University Of Miami

20110183928 - 3-cyanoalkyl- and 3-hydroxyalkylindoles and use thereof: The present application relates to novel 3-cyanoalkyl- and 3-hydroxyalkyl-substituted indole derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention... Agent: Bayer Schering Pharma Aktiengesellschaft

20110183929 - Standardized extract and fraction from hancornia speciosa leaves and pharmaceutical composition thereof: The present invention describes a standardized extract obtained from the leaves of Hancornia speciosa Gomes (EHS), popularly known as “mangaba” in Brazil, as well as a standardized fraction with inhibiting activity on the angiotensin converting enzyme (ACE), and vasodilating, anti-hypertensive and antioxidant properties. The invention further relates to the preparation... Agent:

20110183930 - Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives: The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in... Agent: Libragen

20110183931 - Potent lna oligonucleotides for the inhibition of hif-1a expression: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5′-(Gx)TxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link... Agent: Santaris Pharma A/s

20110183932 - Three-component bone cement: A paste is provided from which bone cement can be formed, which is to the largest extent possible bubble-free and has a high impact strength. The paste includes (i) 15-50 weight percent of at least one mono-functional, hydrophobic methacrylic acid ester, (ii) 40-85 weight percent of at least one filler,... Agent: Heraeus Medical Gmbh

20110184046 - Compositions and methods for inhibiting expression of gsk-3 genes: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3.... Agent:

20110184043 - Inhibition of angiogenesis: The present invention relates to the microRNA miR-126 and to inhibitors of miR-126 that regulate angiogenesis. The present invention provides compositions and methods for the inhibition of miR-126 and for the inhibition of angiogenesis in vivo.... Agent: Cornell Research Foundation, Inc.

20110184044 - Methods and compositions for assessment of pulmonary function and disorders: The present invention provides methods for the assessment of risk of developing chronic obstructive pulmonary disease (COPD), emphysema or both COPD and emphysema in smokers and non-smokers using analysis of genetic polymorphisms.... Agent: Synergenz Bioscience Limited

20110184041 - Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the action or production of PTHrP, its isoforms or PTHrP signalling. An aspect of the present invention is also directed to methods... Agent:

20110184042 - Rna aptamer specifically binding to carcinoembryonic antigen and use thereof: Provided are RNA aptamer specifically binding to cancer metastasis-inducing domain of CEA (Carcinoembryonic antigen), a composition for prevention and/or inhibition and/or diagnosis of cancer metastasis containing the same as an active ingredient, and a method of prevention and/or inhibition and/or diagnosis of cancer metastasis using the same.... Agent: Posco

20110184047 - Rnai modulation of scap and therapeutic uses thereof: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a... Agent:

20110184045 - Silencng and rig-i activation by dual function oligonucleotides: The invention describes a method of determining whether a double stranded RNA (dsRNA) silences gene expression in a cell in vivo by an RNA interference (RNAi) mechanism by performing 5′-rapid amplification of cDNA ends (5′RACE) to detect the cleavage site of the mRNA in the RNA sample.... Agent:

20110184052 - Arginase ii: a target for the prevention and treatment of atherosclerosis: The instant invention provides methods and compositions for the treatment of. atherosclerotic disease. Specifically, the invention provides methods and compositions for modulating the activity of Arginase II, the production of Arginase II or the amount of free Arginase II for the treatment of atherosclerotic disease.... Agent: The Johns Hopkins University

20110184049 - Liver-specific nucleic acid regulatory elements and methods and use thereof: The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using... Agent: Universiteit Gent

20110184050 - Methods and means for treating dna repeat instability associated genetic disorders: The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and/or an uracile and/or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably RNAse H substantially independent and being complementary only to a repetitive sequence in a human gene... Agent: Prosensa Holding Bv

20110184053 - Novel nucleic acid transfer system: The invention relates to a complex formed by at least one molecule of nucleic acid comprising between 10 and 40 nucleotides, covalently coupled to at least one hydrocarbon compound that is at least C18 is hydrocarbon compound, having a squalene structure or a structure similar thereto.... Agent: Universite Paris Sud

20110184051 - Pharmacological applications of mitochondrial dna assays: The invention provides assays to determine the relative amount of mitochondrial DNA in a subject, such as a subject undergoing drug treatment. The subject may for example be a human patient undergoing treatment for an HIV infection with a nucleic acid precursor such as a nucleoside or nucleotide analogue. The... Agent:

20110184048 - Uses and compositions comprising mirnas: The cardiac-specific miRs, miR-133 and miR-1, are critical in determining hypertrophy of cardiac myocyte cells (CMC), and that restoration of levels of expression thereof can alleviate the symptoms of CMC hypertrophy.... Agent:

20110183933 - Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell... Agent:

20110183935 - Heartwater: There is provided a water product for general consumer comprising water suitable for human consumption and a food additive in the amount effective to alter a level of serum marker that indicates a likelihood of cardiovascular disease, thereby the water product is intended to lower the risk of cardiovascular disease... Agent:

20110183934 - Methods and compositions to improve germ cell and embryo survival and function: Sperm, oocyte, and embryo survival and function is improved in vivo or in vitro by the use of a polysaccharide containing arabinose, galactose and/or hexuronic acid. In particular, a nonspermicidal lubricant containing such a polysaccharide (e.g., gum arabic, pectin, or galacturonic acid) increases the fertilization potential of the sperm during... Agent: Bio-origyn LLC

20110183936 - Regimens for intra-articular viscosupplementation: The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5%... Agent: Genzyme Corporation

20110183938 - 1,7-diazacarbazoles and methods of use: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the... Agent: Genentech, Inc.

20110183937 - Agent for combating ectoparasites: Disclosed is a composition for killing ectoparasites and/or their eggs, comprising at least one volatile, at room temperature liquid, non-polar organic solvent, 1 to 10 wt.-%, based on the total composition, of at least one spreading agent; and 35 to 65 wt.-%, based on the total composition, of at least... Agent:

20110183939 - Novel pyrolinone derivative and pharmaceutical composition comprising the same: wherein Z1 is optionally protected hydroxy, etc.; Z2 is —C(═O)—, etc.; Z3a and Z3b are taken together ═O or ═S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer... Agent: Shionogi & Co., Ltd.

20110183940 - Chemical compounds: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent:

20110183941 - Herbicide consisting of a glyphosate formulation containing a surfactant consisting in a branched alkyl alcohol polyethoxylated or polypropoxylated and a mixture of alkylamines: e

20110183942 - Methods and compositions for treating alzheimer's disease: A method is disclosed for inhibiting the build-up of amyloid plaques in the brain of a patient with at least one risk factor for, or a diagnosis of, Alzheimer's Disease by administering to the patient an amount of one or more compounds effective to inhibit the phosphorylative activity of eEF2K,... Agent: Johns Hopkins University

20110183943 - Concurrent therapy regime/regimen for the treatment of acne related diseases: A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy.... Agent: Galderma Research & Development

20110183944 - Sustained-release nsaid/hmg coa reductase inhibitor compositions: Compositions for controlled release of one or more therapeutic agents where the composition is essentially free of excipients are disclosed. In particular, compositions comprising a HMG-CoA reductase inhibitor, particularly simvastatin, and a NSAID, such as a COX-2 inhibitor, particularly celecoxib, in which greater than 90% of the weight of the... Agent:

20110183945 - Long acting curcumin derivative, preparation method and pharmaceutical use thereof: The invention provides a long acting curcumin derivative, preparation method and pharmaceutical use thereof, wherein said long acting curcumin derivative having the general structural formula disclosed herein, wherein R1 and R2 are hydrogen or methoxyl; R3 and R4 are each independently selected from C1-C50 alkyl. Compared with cuminoids, the inventive... Agent: Beijing Dingguochangsheng Biotech., Co., Ltd.

20110183946 - Complexes comprising alpha2-adrenergic receptor agonists and methods of providing neuroprotection or treating or inhibiting progression of glaucoma: A complex comprises at least an α2-adrenergic receptor agonist and a compound that provides an opposite charge to a charge on the α2-adrenergic receptor agonist, wherein the complex is charge neutral as a whole and has a solubility in a range from about 0.3 μg/ml to about 2.5 mg/ml in... Agent:

20110183947 - Alpha-keto heterocycles as faah inhibitors: The invention provides a series of -αketoheterocyclic compounds, for example, compounds of formula (I). The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula (I), useful intermediates for... Agent: The Scripps Research Institute

20110183948 - Treatment of fibrotic conditions using hedgehog inhibitors: Provided is a method of treating a fibrotic condition with a hedgehog inhibitor.... Agent: Infinity Pharmaceuticals, Inc.

20110183950 - Treatment of vaginal atrophy in women with tumor pathology risk: The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women, said women having a high probability of developing an estrogen-dependent tumor... Agent: Italfarmaco, S.a.

20110183949 - Use of fulvestrant in the treatment of resistant breast cancer: The invention relates to the use of fulvestrant in the treatment of breast cancer in patients who have previously been treated with a Selective Estrogen Receptor Modulator (SERM) and an aromatase inhibitor.... Agent:

20110183951 - Copper (1) complex: A Copper (I) chloride complex of pyrazinic acid having the empirical formula C10H12ClCuN4O6 is prepared, further characterized by its crystal structure, described as “CuCl (pyrazinic acid)2.2H2O”, or “CuCl (pyrazinic acid)2.H2O” and more fully detailed as attached hereto. This compound is effective to cure or ameliorate, when mixed into a pharmaceutically... Agent:

20110183956 - Process for the synthesis of ezetimibe and intermediates useful therefor: The present invention discloses novel and useful intermediates for the synthesis of ezetimibe (EZT), which intermediates share a characteristic Z-isomeric structure. Based on Z-5-(4-fluorophenyl)-pent-4-enoic acid, and proceeding the synthesis through further Z-intermediates, a total synthesis is presented to obtained final ezetimibe in high yields.... Agent:

20110183959 - P38 kinase inhibiting agents: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other... Agent:

20110183960 - Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof: The subject matter of the invention is compounds corresponding to formula (I), in which: R1 and R2, together with the nitrogen atom to which they are attached, constitute a saturated heterocyclic radical containing from 4 to 7 atoms, which is preferably substituted; one of the two substituents R3 and R6... Agent: Sanofi-aventis

20110183961 - Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof: The invention relates to compounds of the formula (I) where: R is a (C1-C6)alkyl group, a halo(C1-C6)alkyl group; R1 is a hydrogen atom; R2 is a heterocyclic group bound by a carbon atom, a heterocyclic-(C1-C4)alkyl group, said groups being optionally substituted; R3 and R4 represent independently from each other an... Agent: Sanofi-aventis

20110183955 - 2-aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitors (iap) modulators: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases.... Agent: Novartis Ag

20110183958 - Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azetidine derivatives of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer; liver... Agent: Merck Frosst Canada Ltd.

20110183957 - Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an... Agent:

20110183952 - New chemical compounds: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.... Agent: Boehringer Ingelheim International Gmbh

20110183953 - Selective heterocyclic sphingosine 1 phosphate receptor modulators: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with... Agent:

20110183954 - Tricyclic 2,4-diamino-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders: The present invention relates to compounds of Formula (I): (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.... Agent: Astrazeneca Ab

20110183962 - Smoothened antagonism for the treatment of hedgehog pathway-related disorders: The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli... Agent: Novartis Ag

20110183963 - Amino acid conjugates of quetiapine, process for making and using the same: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.... Agent:

20110183964 - Hydroxamate-based inhibitors of deacetylases b: e

20110183965 - 6-aminoisoquinoline compounds: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and... Agent: Aerie Pharmaceuticals, Inc.

20110183966 - Aminopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20110183967 - Benzoxazole compounds and methods of use: The present invention provides benzoxazole compounds and pharmaceutically acceptable salts thereof and pharmaceutical compositions including the same. The present invention further provides methods of use as described herein.... Agent: Eisai R&d Management Co., Ltd.

20110183968 - Antifungal compounds containing benzothiazinone, benzoxazinone or benzoxazolinone and process thereof: The present invention discloses novel compounds of the Formula (1), comprising benzothiazinone, benzoxazinone or benzoxazolinone moieties having antifungal activity, method for preparing these compounds and the use of these compounds as antifungal agents in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds.... Agent: Council Of Scientific & Industrial Research

20110183969 - Antifungal combination therapy: The invention provides pharmaceutical combinations comprising a combination of an antifungal indolizine compound of formula (I) or a pharmaceutically acceptable salt thereof and a second antifungal agent: wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. The invention also provides pharmaceutical compositions comprising an... Agent:

20110183970 - Insecticide compositions and process: e

20110183971 - 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them: Compounds which are 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected... Agent: Nerviano Medical Sciences S.r.l.

20110183972 - Aromatic ring fused triazine derivatives and uses thereof: The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses... Agent: Shenyang Pharmaceutical University

20110183974 - 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer,... Agent:

20110183975 - Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity: The present invention relates to a compound of formula I: wherein: R1 is C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, or —COR1x, where the C1-6 alkyl, C3-8 cycloalkyl, aryl, and heterocyclyl may be substituted; and R1x is C3-8 cycloalkyl, aryl, or heterocyclyl, any of which may be substituted; R2, R3, R4,... Agent:

20110183973 - Novel compounds: The invention is directed to certain novel compounds directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.... Agent:

20110183976 - 5- and 6-membered heterocyclic compounds: 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is... Agent:

20110183977 - Benzene, pyridine, and pyridazine derivatives: wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions... Agent: Serenex, Inc.

20110183979 - Nitrogen-containing heteroaryl derivatives: e

20110183978 - Phenylpyri(mi)dinylazoles: wherein the symbols have the meanings stated in the description, and agrochemically active salts thereof and the use thereof for the control of undesired microorganisms in the protection of plants and materials and for the reduction of mycotoxins in plants and plant parts and methods for the production of compounds... Agent: Bayer Cropscience Ag

20110183981 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are... Agent: Array Biopharma Inc.

20110183980 - O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators: In one aspect, the invention relates to O-benzyl nicotinamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated... Agent:

20110183982 - Phenoxy acetic acids as ppar delta activators: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-δ and should be useful for treating conditions mediated by the same.... Agent: High Point Pharmaceuticals, LLC

20110183983 - Heterocyclic compound as protein kinase inhibitor: Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound.... Agent: Neopharm Co., Ltd.

20110183986 - Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors: Polycyclic aryl and polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl catalytic activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110183984 - Small molecule inhibitors of lck sh2 domain binding: The present invention provides materials and methods for modulating an immune response. The materials and methods may be used to treat diseases associated with an aberrant immune response. In some embodiments, materials and methods of the invention may be used to treat autoimmune diseases, for example, rheumatoid arthritis.... Agent:

20110183985 - Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors: e

20110183988 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain... Agent:

20110183989 - Saturated bicyclic heterocyclic derivatives as smo antagonists: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example... Agent: Instituto Di Ricerche Di Biologia Molecolare P. Ang

20110183987 - Stereoselective synthesis of bicyclic heterocycles: and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia... Agent: Boehringer Ingelheim International Gmbh

20110183990 - Method of treating atrial fibrillation: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof.... Agent: Gilead Sciences, Inc.

20110183991 - 5ht7 receptor ligands and compositions comprising the same: The present invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, especially as agonists, identified by using a pharmacophore and a descriptor's profile filter as well as to pharmaceutical compositions comprising them. These compounds are useful in therapy in particular for the treatment and or prophylaxis of a... Agent: Laboratorios Del Dr. Esteve, S.a.

20110183992 - Therapeutic agent for migraine: Provided are therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof; therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A2A receptor... Agent: Kyowa Hakko Kirin Co., Ltd.

20110183993 - Cycloalkane derivative: The present invention relates to a novel cycloalkane derivative which has an excellent psychotropic action.... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110183994 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride: The invention relates to new crystalline Modifications of the hydrochloride of 1-[4-(5-cyanoin-dol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoin-dol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2 -carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related... Agent:

20110183995 - Eltoprazine for suppression of l-dopa induced dyskinesias: This invention relates to the use of the drug Eltoprazine for combating dyskinesias arising from chronic Levodopa (L-DOPA) therapy in patients suffering from Parkinson's disease.... Agent: Neurosearch A/s

20110183996 - The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof: The invention discloses 1-butyl-2-hydroxyl aralkyl piperazine derivatives and their use as antidepressants. The derivatives of the present invention have triple inhibition effect on the reuptake of 5-HT, NA and DA, and can be administrated to the patients in need thereof in form of composition by route of oral administration, injection... Agent: Shanghai Institute Of Pharmaceutical Industry

20110183997 - Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors: The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.... Agent: Irm LLC

20110183998 - Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof: Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the... Agent: Sanofi-aventis

20110183999 - Novel polymorphic forms of methyl carbamate: The invention relates to novel forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate of the formula (I), in particular to the modification I, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110184000 - 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivates and their use as pde9a modulators: The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with is a mono-, bi- or tri-cyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in... Agent: Boehringer Ingelheim International Gmbh

20110184001 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20110184002 - Method of treating hepatic disease using a2b adenosine receptor antagonists: The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical... Agent: Gilead Sciences, Inc.

20110184003 - Compounds and methods for the treatment of viral infection: The invention relates to compounds and methods for treating or preventing a viral infection, by administering a monophosphorylated prodrug of acyclovir or monophosphorylated derivative of an acyclovir prodrug to a subject suffering from or susceptible (to a viral infection, such as HIV infection.... Agent: The United States Of America, As Represented By Th

20110184004 - Predictive marker for egfr inhibitor treatment: The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.... Agent:

20110184005 - Predictive marker for egfr inhibitor treatment: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.... Agent:

20110184006 - Method and composition for thermally stabilizing vitamin c within nano layers of montmorillonite clay: A thermally stable Vitamin C composition containing montmorillonite, an organic acid containing L-ascorbic acid or a derivative thereof, a divalent cation present within nanolayers of the montmorillonite, wherein the organic acid is combined with the divalent cation within the nanolayers to form an organic acid-montmorillonite chelate.... Agent: National Research Council Of Sri Lanka

20110184008 - Crystalline forms of an 8-azabicyclo[3.2.1]octane compound: The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.... Agent: Theravance, Inc.

20110184007 - Pharmaceutical compositions configured to deter dosage form splitting: An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject... Agent: Inspirion Delivery Technologies, LLC

20110184009 - Camptothecin derivatives as chemoradiosensitizing agents: Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group... Agent: Catholic Healthcare West Dba St. Mary's Medical Center

20110184010 - Method of treating mantle cell lymphoma: This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.... Agent: Mayo Foundation For Medical Education And Research

20110184011 - Compounds: i

20110184013 - Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors: Compounds of Formula I and II: I II having the chemical names cis-6-fluoro-8-(3-fluoropiperidin-4-yloxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinoline and 6-fluoro-8-(trans-3-fluoropiperidin-4-yloxy)-2-(7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl)quinoline, respectively, and enantiomers and pharmaceutically acceptable salts thereof, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. The compounds of this invention have also... Agent:

20110184012 - Methods and compositions for alleviating stuttering: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of garnma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class... Agent: Endo Pharmaceuticals Solutions Inc.

20110184014 - New compounds: The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I); wherein Y represents a substituent selected from hydrogen, methyl, fluoro, chloro, bromo, methoxy; Z is hydrogen or methyl; R is an optionally substituted heteroaryl, and/or salts and/or hydrates and/or solvates thereof, to the processes... Agent:

20110184015 - Novel derivatives of pyrroloindole which are inhibitors of hsp90, compositions containing same, and use thereof: Pyrroloindoles of formula (I) are provided wherein Het is an aromatic or partially unsaturated, monocyclic or bicyclic heterocycle containing between 1 and 4 heteroatoms N, O or S, optionally substituted by R1 or R′1 which are the same or different; R is X-(A-B)n-CONH2, X-(A-B)n-O—CONH2, X-(A-B)n-NH—CONH2, X—(CH2)m-heterocycloalkyl, X(CH2)m-aryl and X—(CH2)m-heteroaryl wherein... Agent: Sanofi-aventis

20110184016 - Prevention and treatment of itch with cysteine protease inhibition: Embodiments of the invention relates to methods of preventing itch in a subject using a therapeutically effective amount of a cysteine protease inhibitor. The itch is not associated with psoriasis and atopic dermatitis. The itch is also a non-histamine mediated itch. The inhibitor are directed to the cathepsin selected from... Agent: The General Hospital Corporation

20110184017 - Stable aqueous solution composition containing sulfonamide compound: An aqueous solution composition containing (S)-1-(4-chloro-5-isoquinolinesulfonyl)-3-aminopyrrolidine or (S)-1-(4-chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine as an active ingredient, and not containing citric acid or a salt thereof, which has high stability so as to be storable at room temperature.... Agent: Asahi Kasei Pharma Corporation

20110184018 - Method for treating peripheral neuropathic pain: A method for the treatment of peripheral neuropathic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from peripheral neuropathic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.... Agent: Lohocla Research Corporation

20110184019 - Long chain n-alkyl compounds and oxa-derivatives thereof: Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C8-C16 alkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B... Agent: United Therapeutics Corporation

20110184020 - Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions: n

20110184021 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors: A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need... Agent:

20110184022 - Organic compounds: Compounds of formula (I), which are 14-O-{[(optionally substituted hydroxy)cyclohexyl)sulfanyl]acetyl}mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their use as a pharmaceutical, e.g. for the treatment of diseases mediated by microbes and for the treatment of inflammation... Agent: Nabriva Therapeutics Ag

20110184023 - The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide: The present invention relates to the salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl) amino-3-pyridine carboxamide, especially hydrochloride and mesylate thereof, and the use of said salts in the preparation of an antineoplastic medicament.... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20110184024 - Pharmaceutical composition containing esomeprazole: The present invention relates to esomeprazole free base or its alkali salt-containing composition which stability is improved and is easy to manufacture.... Agent: Ctc Bio, Inc.

20110184025 - Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases: Methods of treating, preventing and/or managing a spirochete and/or other obligate intracellular bacterial disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.... Agent:

20110184026 - C4-substituted alpha-keto oxazoles: The invention provides a series of C4-substituted oxazole compounds having an alpha keto side chain at the 2 position, for example, compounds of formula I. The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further... Agent:

20110184027 - Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification: The present invention provides a method of treating a disorder treatable by administering a therapeutically effective amount of a tissue selective Stearoyl-CoA Desaturase 1 (SCD-1) modulator to a subject. In one embodiment, the present invention provides a method of treating a disorder treatable by administering a pharmaceutically effective amount of... Agent: Glenmark Pharmaceuticals S.a.

20110184028 - Derivatives of pyridoxine for inhibiting hiv integrase: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection and AIDS.... Agent:

20110184029 - Pyridone derivatives as non-nucleoside reverse transcriptase inhibitors: e

20110184031 - G-protein-conjugated receptor agonist: Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic... Agent:

20110184032 - Novel phenylamino isonicotinamide compounds: The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation.... Agent: Merck Patent Gmbh

20110184030 - Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate: The present invention is concerned with new polymorphic forms of flupirtine maleate, processes for preparing the new polymorphic forms, pharmaceutical compositions containing them, therapeutic uses thereof and methods of treatment employing them.... Agent: Pliva Hrvatska D.o.o

20110184033 - Selective ligands for the dopamine 3 (d3) receptor and methods of using the same: Potent and selective ligands for the dopamine 3 (D3) receptor are disclosed. The D3 receptor ligands have a structural formula (I) wherein X is C═O or SO2, R1 is C1-6 alkyl, R2 is aryl, heteroaryl, aryl, —(CH2)1-3aryl, or —(CH2)1-3heteroaryl, and n is 0 or 1. Methods of using the D3... Agent: The Regents Of The University Of Michigan

20110184034 - Severe sepsis preventive therapeutic agent: t

20110184035 - Methods of treating degenerative diseases/injuries: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent:

20110184036 - Formulations of bendamustine: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5%... Agent: Eagle Pharmaceuticals, Inc.

20110184037 - Methods for treating an intervertebral disc using local analgesics: Effective methods of treating back pain from an intervertebral disc are provided. The methods of treatment include administering an immediate release analgesic at or near the intervertebral disc; administering a bulking agent or sealing agent within the intervertebral disc; and administering a sustained release analgesic within the intervertebral disc, wherein... Agent: Warsaw Orthopedic, Inc.

20110184038 - Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity: The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any... Agent: Angion Biomedica Corp.

20110184039 - Pharmaceutical formulation: A pharmaceutical composition comprising: a) a 5-HT1 agonist; b) an NSAID; and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.... Agent:

20110184040 - Method for controlling arthropods comprising the spot-wise application of a gel: The present invention relates to a method for controlling arthropods comprising the application of an aqueous gel which contains an insecticide, an attractant and a thickener, wherein the aqueous gel is applied in the form of spots on fruit trees. The invention further relates to an aqueous gel comprising an... Agent: Basf Se

20110184054 - Alpha-lipoic acid concentrate: A water-free concentrate, consisting of ubiquinone Q10, a medium-chained triglyceride or triglyceride mixture, α-lipoic acid and/or its derivative as well as one or more emulsifiers with HLB value between 9 and 19 permitted according to the foodstuff or drug laws has been described.... Agent: Aquanova German Solubilisate Technologies (agt) Gmbh

20110184055 - Therapeutic agents for treatment of ocular hypertension: The invention provides well-defined amides for treating glaucoma and ocular hypertension.... Agent: Allergan, Inc.

20110184057 - Parenteral treatment with statins: Cancer patients, patients with cognitive dysfunction, or patients with pulmonary hypertension are treated with parenterally administered therapeutic doses of statins. Particularly, transdermal, injection employing liquid infusion or particles are employed. For cancer, the statins may be used by themselves or in conjunction with a chemotherapeutic regimen. Liver cancer is treated... Agent:

20110184056 - Use of statins as anticonvulsants, antiepileptics and neuroprotectors: The use of statins as antiepileptic, anticonvulsant, neuroprotector and antioxidant compounds, potentially useful for the prevention and/or treatment of epilepsy, epileptic seizures, convulsions, neurodegenerative diseases, or diseases associated with undesired oxidation, is described.... Agent: Neuron Biopharma, S.a.

20110184058 - Synthesis of 6,7-dihydro-1h-indeno[5, 4-b] furan-8(2h)-one as intermediate in the preparation of remelteon: The present invention describes the preparation of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one, a key intermediate in preparation of ramelteon. The present invention also describes further preceding intermediate compounds useful for the synthesis of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one.... Agent: Lek Pharmaceuticals D.d.

20110184059 - Methylene furanone derivatives and use of said derivatives as a photoprotecting or antioxidant or depigmentation agent in cosmetic or dermatological compositions: e

20110184060 - Oral dosage forms having a high loading of a tranexamic acid prodrug: Oral dosage forms with a high loading of 4-({[(2-methylpropanoyloxy)ethoxy]carbonylamino}methyl)cyclohexanecarboxylic acid are disclosed.... Agent: Xenoport, Inc.

20110184061 - Thiocolchicine and colchicine analogs, methods of making and methods of use thereof: Disclosed herein are thiocolchicine and colchicine analogs and derivatives suitable for use as a muscle relaxant, an anti-inflammatory agent, an anti-gout agent, an anti-proliferative agent, or an anti-cancer agent; methods of making the compounds, and compositions comprising the compounds.... Agent:

20110184062 - Compositions and methods for dry eye syndrome: Compositions and methods to inhibit dry eye as well as other conditions are provided.... Agent:

20110184064 - Therapeutic agent for hepatitis c: Disclosed is a novel therapeutic means against interferon-resistant hepatitis C. Specifically disclosed are: a pharmaceutical composition for treating interferon-resistant hepatitis C, which is characterized by comprising at least one component selected from the group consisting of an ω-3 polyunsaturated fatty acid, a pharmaceutically acceptable salt of the fatty acid and... Agent:

20110184063 - Treatment of neurodegenerative conditions: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linoleic acid residues at... Agent: Btg International Limited

20110184065 - Use of spongosine for the treatment of pain: Use of spongosine (2-methoxyadenosine) as an analgesic, in particular for the treatment of hyperalgesia, is described.... Agent: Cambridge Biotechnology Ltd., A United Kingdom Corporation

20110184066 - Ketoprofen lysine salt-containing aqueous patch: A ketoprofen-containing aqueous patch is provided in which not only operational efficiency in producing is improved, but also the aqueous patch has excellent storage stability and transdermal absorption of ketoprofen. The ketoprofen lysine salt-containing aqueous patch includes a backing layer and an adhesive (paste) layer laminated thereon. The aqueous patch... Agent: Teikoku Seiyaku Co., Ltd.

20110184067 - O-desmethylvenlafaxine succinate polymorph & process for preparing thereof: This disclosure relates to a crystalline form of O-desmethylvenlafaxine and a process for its preparation. The disclosed crystalline form of O-desmethylvenlafaxine can be used for the manufacture of pharmaceutical compositions for the treatment of depression.... Agent: Intas Pharmaceuticals Ltd.

20110184068 - Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators: The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases,... Agent: Newron Pharmaceuticals S.p.a.

20110184069 - Methods and compositions for administration of trpv1 agonists: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions... Agent: Neurogesx, Inc.

20110184070 - Novel compounds, use thereof as medicaments, and method of preparation thereof: m

20110184071 - process for the preparation of amines: The present invention relates to an improved process for the preparation of rasagiline (1) and its pharmaceutically acceptable salts. In particular it relates to a process for preparing rasagiline (1) and its salts substantially free from impurities.... Agent:

20110184072 - Formulation intended to improving the bioavailability of a hydrophobic molecule: The invention relates to a formulation intended to improve the bioavailability by intestinal absorption of polyphenols, comprising at least one polyethylene glycol (and/or functional equivalent(s)) and at least one glycol ether (and/or functional equivalent(s)). The invention is particularly well suited to improving the bioavailability of hydroxystilbenes, particularly 3,5,4′-trihydroxystilbene or resveratrol.... Agent:

20110184073 - Assay: This invention relates to a method of detecting or determining the presence of prostate cancer cells in a sample of body fluid from a subject comprising: (i) isolating cells from said sample to provide a cell sample; (ii) contacting said cell sample with a specific binding member capable of binding... Agent: Cytosystems Limited

  
07/21/2011 > patent applications in patent subcategories. category listing

20110177997 - Cross-beta silk genes: The present invention relates to silk proteins which can be used to produce silk with a cross-beta structure, as well as nucleic acids encoding such proteins. The present invention also relates to recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a... Agent:

20110177996 - Regulatory proteins in lung repair and treatment of lung disease: The DNA-binding protein Sox17 has been found to play an important role in repair of pulmonary tissue after damage, disease, or injury. Nucleic acids encoding proteins involved in pulmonary repair, such as Sox17 and Spdef, can be used as a therapeutic composition for treating pulmonary disease. Methods of treatment of... Agent: Children's Hospital Medical Center

20110177998 - Bioactive peptides and methods of using same: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.... Agent:

20110177999 - Therapeutic combinations useful in treating cftr related diseases: The present invention relates to therapeutic combinations and kits useful in treating CFTR-related diseases, such as cystic fibrosis.... Agent: Vertex Pharmaceuticals Incorporated

20110178000 - Apoptotically active peptides: Specific amino acid sequences and peptides and/or peptide mimetics deducted therefrom influencing apoptosis, and the use thereof for the production of pharmaceuticals as diagnostic tools are shown.... Agent: Cytotools Ag

20110178002 - High affinity ligands bind to clostridium difficile toxin a: Glycans are identified which have high affinity for C. difficile toxin A. They share one of two saccharide backbones and may have additional side chains. The backbones are galactose-β 1-3 N-acetyl-D-glucosamine-β-1-3-galactose-β-1-4-N-acetyl-D-glucosamine and galactose-α-1-3-galactose-β-1-4-N-acetyl-D-glucosamine. The ligands may be used therapeutically, prophylactically, and diagnostically.... Agent:

20110178001 - Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.... Agent: Targanta Therapeutics Corp.

20110178003 - Optimized dengue virus entry inhibitory peptide (10an): The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.... Agent: Florida Gulf Coast University

20110178004 - Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.... Agent:

20110178005 - Compositions and methods for treating disorders associated with overweight animals: The invention encompasses compositions and methods for treating disorders and diseases associated with overweight. The application also encompasses genes differentially expressed in animals and particularly to genes differentially expressed in overweight animals compared to lean animals.... Agent: Hill's Pet Nutrition, Inc.

20110178006 - Method for administering glp-1 molecules: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.... Agent: Emisphere Technologies, Inc.

20110178007 - Spiro-imidazolone derivatives as glucagon receptor antagonists: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and... Agent: Schering Corporation

20110178008 - Compositions for enhancing the production of ppar and/or ppar-associated factors: The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result,... Agent:

20110178009 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons... Agent: Stem Cell Therapeutics Corp.

20110178010 - Use of peptides for promoting wound healing: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical... Agent:

20110178011 - Polysaccharide/bmp complexes which are soluble at physiological ph: A complex of a polysaccharide and recombinant human BMP-2 and BMP-7, soluble at physiological pH, wherein the polysaccharide/BMP mass ratio is less than 15, the polysaccharide being selected from the group of polysaccharides having carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical.... Agent: Adocia

20110178012 - Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy.: Human chorionic gonadotropin administered by intramuscular route is traditionally used for the treatment of sterility and cryptorchidism. After numerous tests performed, a compound to be administered orally—sublingual—has been developed with such drug to treat patients suffering from overweight associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. It... Agent:

20110178013 - Novel octapeptide compounds derived from somatostatin and the therapeutic use thereof: The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical... Agent: Le Centre National De Recherche Scientifique (cnrs)

20110178014 - Prevention and treatment of cardiac arrhythmias: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of... Agent: Amylin Pharmaceuticals, Inc.

20110178015 - Methods of treatment using biased ligands for receptors such as the pth receptor: Disclosed are compositions and methods for modulating the β-arrestin pathway selectively over the G protein pathway of a G protein couple receptor, such as parathyroid hormone receptor.... Agent:

20110178016 - Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation: Currently there is no treatment for hematopoietic syndrome following radiation exposure. Exposed persons are presently treated with blood transfusions, growth factors such as G-CSF to promote neutrophil recovery. Present methods are targeted towards the bone marrow microenvironment, aiding in repair and regeneration with a decrease in the severity or possibly,... Agent: The Board Of Trustees Of The University Of Illinois

20110178017 - Modified vasoactive intestinal peptides: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency,... Agent: Phasebio Pharmaceuticals, Inc.

20110178018 - Novel selenium-containing compounds: A novel selenium-containing compound, a method of producing the selenium-containing compound, an analysis method using the selenium-containing compound, and use of the selenium-containing compound as an antioxidant, are disclosed. A novel selenium-containing compound shown by any of chemical formulas 1 to 4 is obtained by extracting a selenium-containing compound from... Agent: Fisheries Research Agency

20110178019 - New protecting compositions for recombinantly produced factor viii: n

20110178020 - Methods and compositions for inhibition of neutrophil exocytosis: Isolated fusion polypeptides are provided that are comprised of a cell-penetrating polypeptide and a SNARE polypeptide aptamer. Further provided are methods for inhibiting neutrophil granule exocytosis that comprise contacting a neutrophil with a fusion polypeptide including a cell-penetrating polypeptide and a SNARE polypeptide aptamer such that the fusion polypeptide enters... Agent: University Of Louisville Research Foundation, Inc.

20110178021 - Opiorphin for use as a psychostimulant agent: The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and... Agent: Institut Pasteur

20110178022 - Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least... Agent: University Of Copenhagen

20110178024 - Amyloid beta-peptides and methods of use thereof: The present invention relates to polypeptides, compositions, and methods of use thereof for optimized treatment of diseases or disorders associated with amyloid beta protein (Aβ) accumulation in a subject. This invention also relates to polypeptides, compositions, and methods of use thereof for optimized immunization against diseases characterized by Aβ accumulation... Agent: Ben Gurion University Of The Negev Research And Development Authority

20110178023 - Use of sco-spondin peptides for inhibiting or preventing neuronal apoptosis mediated by cell death receptor ligands: The invention relates to a polypeptide derived from the TSR (thrombospondin type 1 units) of SCO-Spondin for inhibiting or preventing the apoptosis mediated by the cell death receptor ligands, such as TRAIL or FasL. The polypeptide of the invention comprises a sequence -W-S-A1-C-S-A2-C-G- wherein A1 and A2 are amino acid... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110178025 - Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.... Agent: University Of Kentucky Research Foundation

20110178026 - Ricin-like toxins for treatment of cancer: The present invention provides a protein having chain of a ricin-like toxin, a B chain of a ricin-like toxin and a novel heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a specific protease such as those found in... Agent: Twinstrand Therapeutics Inc.

20110178027 - Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents: Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and... Agent:

20110178028 - Method for the detection of proventricular dilatation disease and kit thereof: A ganglioside or a mixture of gangliosides, isolated from the peripheral and central nervous system of a bird, in particular a parrot, their use for the preparation of a medicament, methods for the diagnosis of Proventricular Dilatation Disease and diagnostic kits thereof, are disclosed.... Agent:

20110178030 - Methods of treating inflammatory intestinal disease and managing symptoms thereof: Methods and products are disclosed for treating an inflammatory intestinal disease in a mammalian subject in need thereof, or preventing or reducing a symptom of inflammatory intestinal disease. These method include administering to the subject a therapeutically effective dose of (i) an isolated AvrA protein or polypeptide fragment thereof or... Agent: University Of Rochester

20110178029 - Modified human apolipoprotein a-1 and their uses: Modified human apolipoprotein A-I polypeptides and uses thereof are provided.... Agent: Ambrx, Inc.

20110178031 - Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.... Agent: Cti Bio

20110178033 - Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture: e

20110178032 - Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders: This invention relates to methods of using the monoglyceride of acetoacetate and metabolic precursors for the treatment, prevention, inhibition or alleviation of neurological diseases associated with neuronal hypometabolism, such as Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia... Agent: Accera, Inc.

20110178035 - Method for obtaining pure monosialoganglioside gm1 for medical use: A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using... Agent: Laboratoire Medidom S.a.

20110178034 - Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.... Agent: Corixa Corporation

20110178036 - Novel spinosyn-producing polyketide synthases: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.... Agent:

20110178037 - Hydrophobically enhanced aminoglycosides: Hydrophobically enhanced aminoglycosides have been prepared and shown to be effective antibacterial agents. These agents may be used in the treatment or prevention of various bacterial infections. Methods of preparing these agents also permit facile synthetic access. Formula (I).... Agent: University Of Manitoba

20110178038 - Indole antiviral compositions and methods: The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated... Agent: The Regents Of The University Of Michigan

20110178154 - gene expression profile that predicts ovarian cancer subject response to chemotherapy: A gene profiling signature is disclosed herein. The gene signature can predict whether a subject with ovarian cancer will be chemorefractory, chemoresistant or chemosensitive. Thus, methods are disclosed for determining whether a subject with ovarian cancer is sensitive to treatment with a chemotherapeutic agent. Methods are also provided for increasing... Agent:

20110178160 - Inhibition of interaction of psd93 and psds95 with nnos and nmda receptors: PSD-95/SAP90 antisense-treated animals not only experience a significant decrease in MAC for isoflurane, but also experience an attenuation in the NMDA-induced increase in isoflurane MAC. PSD-95/SAP90 appears to mediate the role of the NMDA receptor in determining the MAC of inhalational anesthetics. Suppression of the expression of PSD-95/SAP90 in the... Agent: The Johns Hopkins University

20110178159 - Inhibitory rnas that regulate hematopoietic cells: Provided are compositions and methods for preventing, treating, ameliorating or diagnosing conditions or diseases involving a myeloid cell proliferation disorder. Such compositions and methods target miRNA function myeloproliferative diseases. More particularly, such compositions and methods target miR-29a function in myeloid cell proliferation disorders. Also provided are methods for diagnosing risk... Agent:

20110178156 - Method of suppressing prb deficiency-induced tumor formation: The present invention provides methods of determining a putative agent that inhibits tumorigenesis in retinoblastoma protein deficient cells, the methods comprising determining whether the putative agent decreases phosphorylation of threonine residue 187 of p27, decreases S-phase kinase-associated protein 2 interaction with p27 having a phosphorylated threonine residue 187, or an... Agent:

20110178153 - Methods of treating chemoresistance and relapse in cancer cells: Methods of treating or preventing chemoresistance or relapse growth of cancer cells are provided. Methods of treating or preventing resistance to tyrosine kinase based chemotherapeutic treatment in hematologic and solid tumors are provided. BCR-ABL drug resistance in chronic myelogenous leukemia (CML) and models for conducting further study on the same... Agent:

20110178157 - Modulation of hsp47 expression: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA))... Agent: Quark Pharmaceuticals, Inc.

20110178158 - Set of antiangiogenic molecules and use thereof: The present invention relates to an antiangiogenic pharmaceutical composition comprising at least one molecule selected from the group comprising an antisense nucleic acid molecule of VEGF 165, an antisense nucleic acid molecule of alpha-9 domain that forms integrin alpha-9/beta-1 and an antisense nucleic acid molecule of VAP-1, a molecule of... Agent:

20110178155 - Silencing of csn5 gene expression using interfering rna: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating... Agent: The Usa, As Represented By The Secretary, Dept.of Health And Human Services

20110178161 - Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic; hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in... Agent: Antisoma Research Limited

20110178164 - Application on monoolein as a new helper lipid in transfection: An application of monoolein-based cationic lipid systems can be used for the complexation, transport and transfection of genetic material into target cells. The lipid systems can be prepared through the conjugation of the neutral lipid monooleoyl-rac glycerol (Monoolein) with the cationic tensioactives derived from Dioctadecyldimethylammonium (DODAX) as, for example, Dioctadecyldimethylammonium... Agent:

20110178163 - Mir-182 in the diagnosis and treatment of cancer: The present disclosure provides methods of determining the levels of BRCA1 in a cell, altering the levels of BRCA1 in a cell, determining the likelihood of developing cancer, and determining the prognosis of a patient with cancer using miR-182 and analogs thereof. Importantly, the invention also provides methods of determining... Agent:

20110178162 - Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding... Agent: Medical University Of South Carolina

20110178039 - Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them: Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit... Agent: Aventis Pharma S.a.

20110178041 - Heterocyclic biaryl derivative and pde inhibitor comprising same as active ingredient: i

20110178040 - Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds: There is presently provided methods for delivering an anti-fibrotic or anti-cancer agent to a cell. The methods comprise contacting a cell with an effective amount of imidazolium and imidazolinium compounds as described herein, including imidazolium and imidazolinium salts.... Agent: Agency For Science, Technology And Research

20110178042 - Hydroxamic acid derivatives useful as antibacterial agents: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L1-L4 A, B, R1-R4 and m are as defined herein. The invention also relates... Agent: Pfizer Inc.

20110178043 - Inhibitors of the mevalonate pathway of streptococcus pneumoniae: Compounds and related methods as can be used for selective mevalonate pathway inhibitors.... Agent:

20110178044 - Transdermal administration of hydrophilic drugs using permeation enhancer composition: Methods, formulations, and drug delivery systems are provided for enhancing the flux of a transdermally administered hydrophilic drug using a basic permeation enhancer composition. The enhancer composition contains an inorganic hydroxide and a weaker, nitrogenous base, wherein the bases are selected such that a 0.1M aqueous solution of the nitrogenous... Agent:

20110178045 - Method to induce fatty liver in animal: The present invention discloses a method to induce fatty liver in an animal. The steps of the method comprise: feeding an animal with a high calorie diet, and injecting a mitochondrial inhibitor into the animal to inhibit the mitochondrial activity of the animal, then resulting in fat accumulation and inflammation... Agent: Taipei Medical University

20110178046 - Methods for treating glioblastoma: Described are methods for treating cancers, e.g., glioblastoma, including administering an inhibitor of Notch signalling, e.g., a gamma secretase inhibitor, in combination with a chemotherapeutic agent.... Agent: University Of Massachusetts

20110178047 - Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same: Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of... Agent: Martek Biosciences Corporation

20110178049 - Avermectin/hydrocortisone compositions for treating afflictions of the skin. e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Galderma S.a.

20110178048 - Stabilized formulation of triamcinolone acetonide: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.... Agent:

20110178051 - Topical skin care composition: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.... Agent: Galderma S.a.

20110178050 - Use of cyclolignans for the treatment of a hyperactive immune system: There is disclosed use of certain picro derivatives of cyclolignans for prophylaxis or treatment of diseases or conditions characterised by a hyperactive immune system. Examples of cyclolignans according to the invention include picropodophyllin, deoxypicropodophyllin, anhydropicropodophyllol or deoxyanhydropicropodophyllol. Formula (I)... Agent: Axelar Ab

20110178052 - 9-alpha estratriene derivatives as er-beta selective ligands for the prevention and treatment of intestinal cancer: e

20110178053 - Azacarboline derivatives, preparation method thereof and therapeutic use of same: The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF3; substituted oxy, optionally substituted alkoxy; optionally substituted amino; substituted carbonyl; optionally substituted carboxyl; optionally substituted amide; sulphur, such as optionally substituted sulphones, sulphoxides or sulphides; linear, branched or cyclic C1-C10 alkyl optionally comprising... Agent: Sanofi-aventis

20110178059 - 1,3-oxazolidin -2-one derivatives useful as cetp inhibitors: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to... Agent: Merck Sharp & Dohme Corp.

20110178057 - Heterocyclic compound and use thereof: Compounds represented by the formulas (I) (II) wherein each symbol is as defined in the specification, and a pro-drug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.... Agent: Takeda Pharmaceutical Company Limited

20110178058 - Inhibitors of flaviviridae viruses: m

20110178060 - Nitrogen-containing heterocyclic compound and use of same: is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and... Agent: Takeda Pharmaceutical Company Limited

20110178056 - Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with... Agent:

20110178055 - Dual nk1/nk3 receptor antagonists: wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing... Agent:

20110178054 - Heterocyclic gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.... Agent: Prosidion Limited

20110178061 - Heterocyclic derivatives for modulation of calcium channels: Heterocyclic derivatives act as Ca channel antagonists. The compositions are useful for treating or relieving Ca channel mediated conditions.... Agent: Vertex Pharmaceuticals Incorporated

20110178063 - Benzpyrazol derivatives as inhibitors of pi3 kinases: The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.... Agent: Glaxo Group Limited

20110178062 - Indole and benzothiophene compounds as modulators of the histamine h3 receptor: Certain substituted indole and benzothiophene compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent:

20110178064 - Spiro condensed barbituric acid derivatives for use as antibacterial: In one aspect, the present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to method for their preparation.... Agent: Astrazeneca R&d

20110178065 - Novel cyp17 inhibitors: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.... Agent: Biomarin Pharmaceutical Inc.

20110178066 - Hydroxypiperidine derivatives and uses thereof: Chemical agents, such as derivatives of hydroxypiperidine moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene... Agent:

20110178067 - Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases: e

20110178068 - Quaternary ammonium salt prodrugs:

20110178069 - Inhibitors of interleukin-1 beta converting enzyme: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly... Agent: Vertex Pharmaceuticals Incorporated

20110178070 - Pi3k/mtor inhibitors: e

20110178071 - Antiviral treatments: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.... Agent:

20110178072 - Stereospecificity of methylsulfinyl reduction: This disclosure relates to compositions and methods of use involving compounds (e.g., drugs) containing methylsulfinyl moieties. For example, a compound may be administered in an excess of either the R- or S-epimer of the methylsulfinyl moiety based on whether the compound exhibits higher biological activity when the methylsulfinyl moiety is... Agent:

20110178073 - Methods of improving cognitive functions: Methods and articles of manufacture for use in improving a cognitive function, utilizing a conjugate comprising a first moiety having GABA agonist activity and a second moiety having CNS activity being covalently linked to the first moiety, are disclosed. Also disclosed are methods and articles of manufacture of preventing onset... Agent:

20110178074 - Antipathogenic benzamide compounds: t

20110178075 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act... Agent:

20110178076 - Medical intervention in haematological cancers: The present invention relates to the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines, in particular Imiquimod® and Gardiquimod®, alone or preferably in combination with Akt inhibitors, in particular with Akti1/2 and AktX, and most preferably with Akti1/2, in the treatment, prevention and/or amelioration of haematological cancers, in particular multiple myeloma... Agent: Medizinische Universitat Innsbruck

20110178077 - Anti-infective compounds: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.... Agent:

20110178078 - Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof: wherein: X═S, SO or NH; R1 represents hydrogen, optionally substituted C1-C3alkyl, cycloalkyl, adamantyl, aryl or heterocyclyl; R2 represents hydrogen, halogen, optionally substituted C1-C3alkyl, substituted hydroxyl, aryldiazenyl or optionally substituted amino group; R3 represents hydrogen, optionally substituted C1-C3alkyl, substituted hydroxyl, pyridyl or optionally substituted amino group, besides, in cases when X═S... Agent:

20110178079 - Guanidine compounds as anesthetics and for treatment of nervous system disorders: e

20110178080 - Melanocortin receptor-specific spiro-piperidine compounds: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one... Agent: Palatin Technologies, Inc.

20110178081 - Pyrazolo pyridine derivatives as nadph oxidase inhibitors: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Genkyotex Sa

20110178082 - Pyrazolo pyridine derivatives as nadph oxidase inhibitors: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Genkyotex Sa

20110178083 - Pde-10 inhibitors: Vicinal substituted cyclopropyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function, for example neurological, neurodegenerative... Agent:

20110178084 - Therapeutic compounds: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20110178086 - Adamantyl diamide derivatives and uses of same: m

20110178087 - Compositions and their use as anti-tumor agents: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not... Agent: Compass Pharmaceuticals LLC.

20110178085 - Salts of n-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide: Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide are prepared and characterized.... Agent: Novartis Ag

20110178088 - Tetrahydro-naphthalene derivatives: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment... Agent: Xention Limited

20110178089 - 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds: i

20110178091 - Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders: The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical... Agent: Green Cross Corporation

20110178090 - Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof: where R1, R2, R5, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof (a “Substituted-Quinoxaline-Type Bridged-Piperidine Compound”), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective... Agent:

20110178092 - Hiv-1 protease inhibitors: Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection.... Agent:

20110178093 - Tetrasubstituted pyridazines hedgehog pathway antagonists: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.... Agent: Eli Lilly And Company

20110178094 - Oral formulation: The invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and to a composition comprising the compound.... Agent: H. Lundbeck A/s

20110178095 - Tyrosine kinase inhibitors containing a zinc binding moiety: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Curis, Inc.

20110178096 - Octahydropentalene compounds as chemokine receptor antagonists: pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases... Agent: Abbott Laboratories

20110178097 - Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts: The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention... Agent: Novartis Ag

20110178099 - Pharmaceutical combination: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising... Agent: Boehringer Ingelheim International Gmbh

20110178098 - Anticancer compounds and methods of making and using same: In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes... Agent:

20110178100 - Apoptosis inhibitor: It is directed to provide a novel apoptosis inhibitor. Specifically directed is an apoptosis inhibitor containing a biphenylcarboxamide compound represented by the following formula (1) as an active ingredient, wherein R1 represents a hydrogen atom or a lower alkoxy group; R2 represents a hydrogen atom or a lower alkanoyl group;... Agent: Nihon University

20110178101 - Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and... Agent:

20110178102 - Sir2 regulation: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20110178103 - Therapeutic agent for chronic renal failure: The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by... Agent: Toray Industries, Inc.

20110178104 - Anti-heparin compounds: The present invention provides compounds and methods for antagonizing the anticoagulant effect of an anticoagulant agent that is selected from UFH, LMWH, and a heparin/LMWH derivative in a patient comprising administering to the patient a compound of the invention or a salt thereof, or a composition comprising the same.... Agent: Polymedix Inc.

20110178105 - Clinical benefits of eicosapentaenoic acid in humans: Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 [“Lp-PLA2”] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 Score™ in humans, by administering an effective amount of eicosapentaecnoic acid [“EPA”], an omega-3 polyunsaturated fatty acid [“PUFA”].... Agent: E.i. Du Pont De Nemours And Company

20110178106 - 5-quinolinone and imidazopyridine compounds and use thereof: 5-Quinolinone and Imidazopyrimidine compounds are provided that are useful for inhibiting the efflux of any therapeutic agent that is a MRP1 substrate. Also provided is a method for screening to identify additional MRP1 inhibitors.... Agent: Southern Research Institute Office Of Commercializ

20110178107 - Hcv protease inhibitors: This invention relates to compounds of Formula (I), (II), or (III) shown in the specification. These compounds can be used to treat hepatitis C virus infection.... Agent: Taigen Biotechnology Co., Ltd.

20110178108 - Group of amino substituted benzoyl derivatives and their preparation and their use: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of... Agent: Institute Of Medicinal Biotechnology Academy Of Medical Science

20110178109 - Pest control composition and pest control method: g

20110178110 - Genotype and expression analysis for use in predicting outcome and therapy selection: The invention provides compositions and methods for determining the likelihood of successful treatment with a various treatment regimens available to gastrointestinal cancer patients. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating these patients.... Agent: University Of Southern California

20110178111 - Long-term treatment of symptomatic heart failure: The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called “n-3 PUFA”) as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular... Agent: Sixterpharma S.r.l.

20110178112 - Ppar modulators: 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections.... Agent: Evolva Sa

20110178113 - Methods of treating traveler's diarrhea and hepatic encephalopathy: Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.... Agent: Salix Pharmaceuticals, Ltd

20110178114 - Topical regional neuro-affective therapy: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the... Agent: Afgin Phara LLC

20110178115 - Azaindole derivatives as crth2 receptor antagonists: Compounds of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.... Agent: Merck Frosst Canada Ltd

20110178116 - Methods of stimulating immune response in certain individuals: The present invention is directed to a method of increasing the time period between outbreaks of genital herpes comprising providing an imidazoquinolinamine formulation, disposing an amount of the imidazoquinolinamine formulation into a first nare of an individual infected with Herpes Simplex Virus type 2, covering at least a portion of... Agent:

20110178117 - Oxazolobenzimidazole derivatives: The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also... Agent: Merck Sharp & Dohme Corp.

20110178118 - Palonosetron for the treatment of chemotherapy induced emeses: Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT3 receptor antagonists are disclosed, especially with palonosetron.... Agent:

20110178119 - Bridged n-bicyclic sulfonamido inhibitors of gamma secretase: The invention provides N-bicyclic sulfonamido compounds of Formula (I) wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also... Agent: Elan Pharmaceuticals, Inc.

20110178120 - Hiv integrase inhibitors from pyridoxine: The present invention relates to pyridoxine (vitamin B6) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R1, R2, R4, A, L B1 and B2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme... Agent: Ambrilia Biopharma, Inc.

20110178121 - Methods for treating pain: The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an α7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt.... Agent: Abbott Laboratories

20110178122 - Quinolizidinone m1 receptor positive allosteric modulators: The present invention is directed to quinolizidinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20110178123 - Nonpeptide hiv-1 protease inhibitors: Novel compounds and compositions for treating patients in need of relief from HIV, AIDS, and AIDS-related diseases are described. Methods for treating HIV, AIDS, and AIDS-related diseases using the compounds described herein are also described.... Agent: Purdue Research Foundation

20110178124 - Pyridinium and quinolinium derivatives: The invention provides compounds of formula I blocking phosphorylcholine biosynthesis by means of the selective blocking of the choline kinase enzyme in tumor cells or in cells affected by parasitic infection and therefore being applicable in the treatment of tumors and parasitic diseases or diseases produced by viruses and fungi... Agent: Universidad De Granada

20110178125 - Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount... Agent:

20110178127 - Amine compounds and medical uses thereof: The present invention relates to a new amine compound or a pharmaceutically acceptable salt thereof, wherein the definitions of X, R1, R2 and n are given in the description, to a pharmaceutical composition containing the compound as active ingredient, and to use of the amine compound or its pharmaceutically acceptable... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China

20110178126 - Pyrazolylbenzothiazole derivatives and their use as therapeutic agents: e

20110178128 - Benzimidazole compound in crystal form and salt thereof:

20110178129 - Inhibitors of flaviviridae viruses:

20110178131 - Compounds which have activity at m1 receptor and their uses in medicine:

20110178130 - Macrocyclic urea and sulfamide derivatives as inhibitors of tafia: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.... Agent: Sanofi-aventis

20110178132 - Pyridine compound and use thereof for pest control: (In the formula, R1 represents a C1-C7 alkyl group which may be substituted by a halogen atom, or the like; m represents an integer of 1-5; A represents a single bond, an oxygen atom, a sulfur atom or the like; and R2 represents a C1-C7 alkyl group which may be... Agent:

20110178133 - Calcium receptor modulating agents: The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.... Agent:

20110178134 - Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof: The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.... Agent: Sanofi-aventis

20110178135 - Salts and crystalline forms of a factor xa inhibitor: The present invention provides salts and crystalline forms of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, and pharmaceutical compositions and method of use thereof.... Agent: Millennium Pharmaceuticals, Inc.

20110178136 - Heterocyclic inhibitors of mek and methods of use thereof: wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of... Agent: Array Biopharma Inc.

20110178137 - Diaryl urea for treating heart failure: The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing heart failure and/or connected diseases therewith comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110178138 - Inhibitors of protein prenyltransferases: The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of protein prenyltransferases including GGTase I and/or RabGGTase. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.... Agent: The Regents Of The University Of California

20110178139 - Pyridoxamine for the treatment of diabetic kidney disease: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.... Agent:

20110178140 - Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists: A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition... Agent: Green Cross Corporation

20110178142 - Pharmaceutical composition for therapeutic or prophylactic treatment of bacterial infections and associated diseases: The present invention provides a pharmaceutical composition comprising 3-{5-[4-Oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-5-ylidenemethyl]-furan-2-yl}-benzoic acid or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients for therapeutic or prophylactic treatment of bacterial infections and diseases associated thereof.... Agent: National Institute Of Immunology

20110178141 - Thiazoliums and their use for treating protein aging associated diseases: The present invention relates to a composition of a thiazolium compound of formula I or a solvate thereof, wherein the definitions of groups in the formula I are as those given in the claims:... Agent:

20110178143 - Therapeutic compounds: e

20110178144 - Therapeutic compounds:

20110178145 - Alpha-2 adrenergic agonist having long duration ofintraocular pressure-lowering effect: The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline... Agent: Allergan, Inc.

20110178146 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20110178147 - Compositions and methods for controlling pupil dilation: The disclosure provides a composition for controlling pupil dilation comprising about 0.001% to about 1.0% by weight of an alpha-adrenergic receptor antagonist selected from phentolamine, phentolamine mesylate, or a phentolamine salt; and at least one excipient selected from the group consisting of a buffer, tonicity agent, preservative, antioxidant, surfactant, solubilizer,... Agent: Allergan, Inc.

20110178148 - Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators: e

20110178149 - Ether compounds with nitrogen-containing 5-member heterocycle and uses thereof: The compounds of the present invention have broad-spectrum insecticidal activities, and they are very effective to lepidopterous pests, including Ostrinia nubilalis, sugarcane borer, summer fruit tortrix moth, Grapholitha inopinata, Lymantria dispar, Cnaphalocrocis medialis, Pyrausta nubilalis, Heliothis assulta, Grapholitha molesta, Plutella xylostella, Laphygma exigua, Prodenialitura and the like, especially more effective... Agent:

20110178150 - Use of indole derivatives as nurr-1 activators for treating parkinson's disease: e

20110178151 - Compounds and methods of treating obesity: The present invention relates to novel fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as agents for the treatment of obesity and related disorders, and for improving cognition.... Agent: Yissum Research Development Company Of The Hebrew

20110178152 - Composition comprising s-allylmercapto-n-acetylcysteine (assnac) for up-regulation of cellular glutathione level: The present invention relates to S-allylmercapto-N-acetylcysteine (ASSNAC) and its pharmaceutically acceptable salts and solvates, which are useful for up-regulation of cellular glutathione levels and expression of phase II detoxifying enzymes. The invention further provides methods of use thereof in the prevention, alleviation or treatment of oxidative stress induced by reactive... Agent:

20110178165 - Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I): as defined in the specification. The invention is also directed to compositions containing the compounds of formula (I). They are useful in the treatment of CNS disorders.... Agent: Pfizer Inc.

20110178166 - Methods of using low-dose doxepin for the improvement of sleep: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).... Agent: Somaxon Pharmaceuticals, Inc.

20110178168 - Coumarin compounds for the treatment of cardiovascular diseases and a process for preparing the same: The present invention relates to compounds of Formula (I): wherein—X and Y represent O, S, NR′; Rn represents alkyl, aryl, OR1, NH2, SR1, NR1R2. wherein R1, R2=H, alkyl, phenyl, aryl, OCOR3, SCOR3, NHCOR3, NR1COR3, etc. (wherein R3 represents alkyl, phenyl, aryl, heteroaryl); R′ and R″ represent H, alkyl, phenyl, substituted... Agent:

20110178167 - Method for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen using terminalia catappa leaf extract: A method for inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting the expression of collagen in a mammal is provided, and the method comprises administrating an effective amount of a Terminalia catappa leaf extract to... Agent:

20110178169 - Use of 5-hydroxy-2-hydroxymethyl-y-pyrone (hmp) as a leishmanicidal agent: The present invention refers to the use of HMP (a secondary metabolite obtained from Aspergillus fungi) as an agent that intensifies the mechanism of macrophage activation, leading to the death of L. (Leishmania) amazonensis, the etiologic agent of cutaneous leishmaniasis. The main mechanism of action of this agent is the... Agent:

20110178170 - Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering: The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of cancer. Moreover, the present invention encompasses methods of treatment for said diseases.... Agent: Technical University Of Denmark

20110178171 - Compounds for cancer therapy: e

20110178172 - Inhibitors of carnitin-palmitoyl-tranferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue: Carnitin-Palmitoyl-Transferase-1 (CPT-1) inhibitor for use in treating and/or preventing disorders caused by delipidation of neural tissue.... Agent: Meta-iq Aps

20110178173 - Anti-degradation agent: There is provided an anti-degradation agent capable of exhibiting an excellent deterioration-inhibiting property for foods, cosmetics, etc., showing a good effect even when added in a small amount, having a high heat resistance, and being free from adverse influence due to light. There are provided (1) an anti-degradation agent comprising... Agent: Mitsubishi Chemical Corporation

20110178174 - Salts of tramadol and ibuprofen and their crystal form in the treatment of pain: The present invention relates to salts and compositions of tramadol and ibuprofen, their crystal form, processes for preparation of the same and their uses for the treatment of pain.... Agent: Laboratorios Del Dr. Esteve, S.a.

20110178175 - Method for producing mechanically activated amorphous and amorphocrystalline compounds of gluconic acid calcium salt: The invention relates to the creation of mechanically activated amorphous and amorphocrystalline compounds and compositions of a gluconic acid calcium salt, pharmaceutical preparations based thereon, a method for producing same and use for treatment of a wide range of diseases caused by disorders of calcium metabolism in an organism. A... Agent:

20110178176 - Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses: A method of reducing or inhibiting the contraction or communication of viral illnesses is proposed. Application of a virucidal preparation containing one or more organic acids (e.g. malic acid) with or without a surfactant (e.g. sodium C14-C16 olefin sulfonate) in a carrier agent (e.g. petrolatum) to the face of well... Agent: Nuance Health, LLC

20110178177 - Topical formulations for treatment of neuropathy: Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms... Agent: Taraxos Inc.

20110178178 - Treatment of motor fluctuations: The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.... Agent: Motac Neuroscience Limited

20110178179 - 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus: The present invention relates to the treatment of an individual afflicted with cognitive impairment associated with tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.... Agent: Merz Pharma Gmbh & Co. Kgaa

20110178180 - Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof: Disclosed herein are deuterium-enriched colchicine, thiocolchicine, and derivatives thereof. The deuterium-enriched compounds are useful as, an antiproliferative agent, a muscle relaxant, an anti-inflammatory agent, or an anti-gout agent.... Agent:

20110178181 - Personal care compositions comprising a methyl naphthalenyl ketone or a derivative thereof: A personal care composition comprising a methyl naphthalenyl ketone or a derivative thereof, such as 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2naphthalenyl)-ethan-1-one, for down regulating at least one TRP receptor associated with a pain response, including but not limited to TRPV1 and TRPA1 receptors to reduce skin irritation associated with hair removal.... Agent:

20110178182 - Enriched nanostructure composition: A method of producing a nanostructure composition from a solid powder is disclosed. The method comprises: (a) heating the solid powder, thereby providing a heated solid powder; (b) immersing the heated solid powder in a liquid in the presence of a gas medium, the liquid being colder than the heated... Agent: Do-coop Technologies Ltd.

20110178183 - Use of polyether-based and vinyl monomer-based copolymers as binders for dosing forms comprising solid active ingredients: m

20110178184 - Hydrogel: A hydrogel comprising a polysaccharide, wherein amphiphilic side chains are bonded to the carboxyl groups of a polysaccharide with carboxyl groups on side chains, an inorganic ion other than calcium ion, and water, and a method for its preparation. The gel has high viscoelasticity, can be injected into the body... Agent: Teijin Limited

  
07/14/2011 > patent applications in patent subcategories. category listing

20110172142 - Functional food paste: Food compositions include carbohydrate, fat, and at least about 15 wt. % protein based on the total weight of the composition and a water activity of less than about 0.85 aw when measured at 25 degree celsius or a shelf-life at 25 degree celsius of at least 12 months. The... Agent: Solae, LLC

20110172139 - Peptides whose uptake by cells is controllable: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however,... Agent: The Regents Of The University Of California

20110172140 - Poly-pegylated protease inhibitors: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one... Agent: Dyax Corp.

20110172141 - Process for preparing microparticles: A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 μm, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture... Agent: Critical Pharmaceuticals Limited

20110172143 - Method of modulating cell survival and reagents useful for same: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival... Agent: University Of Queensland, The

20110172144 - Methods for increasing expression of serca2a in cardiac muscle: The present invention relates to methods for augmenting SERCA2 mediated calcium ion transport into the sarcoplasmic reticulum of cardiac myocytes of a host. The method includes administering to host cardiac myocytes a zinc finger protein that induces expression of SERCA2a (or administering a nucleic acid molecule encoding such a protein),... Agent: Celladon Corporation

20110172145 - Antimicrobial compounds: The present invention relates to a compound of formula (I) AA-AA-AA-X—Y—Z wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; X is a... Agent: Lytix Biopharma As

20110172146 - Growth hormone polypeptides and methods of making and using same: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in administration to animals.... Agent: Amunix Operating, Inc.

20110172147 - Neuropeptide-2 receptor (y-2r) agonists: e

20110172148 - Periostin-induced pancreatic regeneration: A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.... Agent: Ottawa Hosptial Research Institute

20110172149 - Method of regulating glucose metabolism, and reagents related thereto: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism... Agent: 1149336 Ontario, Inc.

20110172150 - Tissue regeneration method: The invention relates to the use of haematopoietic growth factors, in particular erythropoietin (EPO) and thrombopoietin (TPO), or derivatives analogues or parts thereof, for promoting structural tissue regeneration.... Agent:

20110172151 - Derivatives of growth hormone and related proteins, and methods of use thereof: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Bolder Biotechnology, Inc.

20110172152 - Treatment of short bowel syndrome patients with colon-in-continuity: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.... Agent: Nps Pharmaceuticals, Inc.

20110172154 - Preventive and/or therapeutic and/or aggravation suppressing agent for human arthritis deformans: t

20110172153 - Screening methods using g-protein coupled receptors and related compositions: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its... Agent: Chugai Pharmaceutical Co., Ltd.

20110172155 - Beta thymosin fragments: Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.... Agent: Regenerx Biopharmaceuticals, Inc.

20110172156 - Methods and compositions for treating bleeding disorders: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having... Agent:

20110172157 - Somatostatin analogues: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.... Agent: Novartis Ag

20110172158 - Targets, methods, and reagents for diagnosis and treatment of schizophrenia: The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms... Agent: Rockefeller University

20110172159 - Proteic acid polymer, production processes, use of proteic acid polymer, pharmaceutical composition and method of treatment: The present invention relates to proteic acid polymers (pLNs) comprising specific properties to reduce tissue damage and improve functional recovery after injury, and the production process of said proteic acid polymers. Those pLNs are preferably obtained using the protein laminin diluted in an acidic pH in the presence of divalent... Agent:

20110172160 - Heat-stable, aqueous lactoferrin composition and its preparation and use: The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected... Agent: Campina Nederland Holding B.v.

20110172161 - Composition for therapeutic and cosmetic botulinum toxin: This invention relates to a composition of botulinum based pharmaceuticals used for therapeutic and cosmetic treatment. This invention offers an improvement on the prior art by eliminating the potential of blood-borne contamination with botulinum based pharmaceuticals. Recombinant serum albumin is taught for use in the place of human serum albumin... Agent: Botulinum Toxin Research Associates, Inc.

20110172162 - Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis: The invention provides, in the treatment of malignant tumors, antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene, in combination with a chemotherapy drug, typically bleomycin, cyclophosphamide, or methotrexate, which otherwise is known to cause lung disease such as pulmonary fibrosis.... Agent:

20110172163 - Novel protease inhibitors: The invention relates to KLK protease inhibitors. In particular, the invention is directed to KLK4 protease inhibitors and their uses in the treatment of a cancer, such as prostate cancer.... Agent: Queensland University Of Technology

20110172164 - Bi-dentate compounds as kinase inhibitors: wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide mimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A... Agent: Sanford-burnham Medical Research Institute

20110172166 - Anionic polysaccharides functionalized by a hydrophobic acid derivative: A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to... Agent: Adocia

20110172165 - Modified linkers: We describe modified peptide linkers that function to link at least first and second polypeptides wherein said modified peptide linker comprises a motif for the addition of a sugar moiety.... Agent:

20110172167 - Formulations of daptomycin: Long term storage stable daptomycin-containing compositions are disclosed. The compositions include daptomycin or a pharmaceutically acceptable salt thereof at a concentration of less than or equal to about 25 mg/mL, a buffer having an acidic functional group and have a pH of from about 6.0 to about 7. The formulations... Agent: Eagle Pharmaceuticals, Inc.

20110172168 - Ilt-2 (lir1) variants with increased affinity for mhc class i molecules: The present invention provides ILT-2 variants having the property of binding to a given Class IpMHC with a KD of less than or equal to 1 μM and/or an off-rate (Koff) of 2 S−1 or slower AND said polypeptide has at least a 45% identity and/or 55% similarity to SEQ... Agent: Medigene Ltd.

20110172170 - Interferon-like protein zcyto21: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.... Agent: Zymogenetics, LLC

20110172169 - Method of detection of nucleic acids with a specific sequence composition: This invention is a novel method for detecting and localizing specific nucleic acid sequences in a sample with a high degree of sensitivity and specificity. The method and novel compositions used in the method involve the use of Probe Nucleic Acids, the production of nucleic acid binding regions and the... Agent:

20110172171 - Taurine or taurine-like substances for the prevention of brain oedema: The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a... Agent:

20110172172 - Method of treating neurological conditions with cardiac glycoside: A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.... Agent: Phoenix Biotechnology, Inc.

20110172173 - Spinosyn antifouling compositions, methods of use thereof and articles protected from attachment of biofouling organisms: Disclosed herein are antifouling compositions including at least one spinosyn active material. These compositions provide protection to surfaces coated or impregnated therewith from attachment of various biofouling organisms. Compositions include, for example, paint, varnish, and sealant formulations.... Agent:

20110172174 - Antibacterial agents: s

20110172175 - Process and composition for coating propagation material: The present invention provides a process for coating a plant propagation material, including a seed, comprising: a.) providing a propagation material, such as seed, to be coated; b.) applying to the propagation material a composition comprising at least one reactant having reactive functionality and, optionally, at least one active ingredient;... Agent: Syngenta Crop Protection, Inc.

20110172176 - Crystal structures of sglt2 inhibitors and processes for preparing same: e

20110172292 - Antidote oligomers: The present invention relates to antidote oligomeric compounds (oligomers), which target nucleotide based therapeutics in vivo, thereby providing a method of controlling the bioavailability and therefore the therapeutic activity and/or side effects of nucleotide based therapeutic in vivo.... Agent:

20110172286 - Cd44 splice variants in neurodegenerative diseases: There is provided a method of treating or preventing a neurodegenerative disease, which includes administration of a composition that includes a reagent capable of modulating expression of ribonucleic acid (RNA) encoded by a nucleic acid, wherein the nucleic acid is selected from a group that includes a contiguous nucleotide sequence... Agent: Neurim Pharmaceuticals (1991) Ltd.

20110172287 - Compositions and methods for inhibiting tumor growth and metastasis: Disclosed are compositions and methods useful in the reduction of p11 protein activity in cancer cells. P11 protein is demonstrated to affect plasmin production and activity, MMP activity, plasminogen activation, antiangiogenic plasmin fragment production, cell invasion, tumor development and metastasis. Compositions that modulate levels of p11 either up or down... Agent:

20110172288 - Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumours: The subject matter relates to newly discovered nucleic acid molecules and proteins associated with thymic lymphoma and hamartomatous tumors. Compositions and methods for detecting, characterizing, preventing, and treating human thymic lymphoma and hamartomatous tumors are provided.... Agent: Dana-farber Cancer Institute, Inc.

20110172294 - Cyclohexenyl nucleic acids analogs: The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclo-hexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding... Agent:

20110172290 - Isoforms of eif-5a: senescence-induced eif5a; wounding-induced elf-5a; growth elf-5a; and dhs: The present invention relates to unique isoforms of eukaryotic initiation Factor 5A (“eIF-5A”): senescence-induced eIF-5A; wounding-induced eIF-5A; and growth eIF-5A, as well as polynucleotides that encode these three factors. The present invention also relates to methods involving modulating the expression of these factors. The present invention also relates to deoxyhypusine... Agent:

20110172293 - Methods and compositions for modulating angiogenesis: The present invention provides compositions comprising antisense nucleic acids that reduce miR-126 levels in an endothelial cell. The present invention provides compositions comprising a target protector nucleic acid. The present invention provides methods of modulating angiogenesis in an individual, the methods generally involving administering to the individual an effective amount... Agent:

20110172289 - Minor groove binder (mgb)-oligonucleotide mirna antagonists: Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are... Agent: Dharmacon, Inc.

20110172291 - Rna interference for the treatment of gain-of-function disorders: The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease.... Agent: University Of Massachusetts

20110172295 - Methods and compositions for the regulation of microrna processing: Provided herein are methods and compositions for the regulation of microRNA processing. The invention presents methods for inhibiting the activity of a Lin-28-like polypeptide and methods for treating a subject with cancer comprising administering to a subject with cancer a compound that inhibits the activity of a Lin-28-like polypeptide. Compositions... Agent: The University Of North Carolina At Chapel Hill

20110172296 - Modulation of transforming growth factor-beta 1 expression: Provided are compounds capable of inhibiting expression of TGF-beta 1 and compositions containing same as well as methods using such compounds for treating fibrotic diseases including the reduction of scarring resulting from wound healing.... Agent:

20110172177 - Combination, kit and method of reducing intraocular pressure: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under... Agent: Inotek Pharmaceuticals Corporation

20110172178 - Beta-l-2' deoxynucleosides for the treatment of resistant hbv strains and combination therapies: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV... Agent: Novartis Ag

20110172179 - Micronutrient formulations for radiation applications: A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide... Agent:

20110172181 - Compositions and methods of aloe polysaccharides: The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune... Agent: North Texas Medical Associates

20110172180 - Heat stable hyaluronic acid compositions for dermatological use: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.... Agent: Allergan Industrie. Sas

20110172182 - Carboxyethylated cyclodextrin polysulfates useful as medicaments: This invention relates to novel β-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment... Agent: Arcarios B.v.

20110172184 - Antitumor agent containing 4 - [[3,5 - bis (trimethylsilyl) benzoyl] amino] benzoic acid: Disclosed is a novel combination therapy of sorafenib having a remarkable antitumor effect. Specifically disclosed is an antitumor agent obtained by combining sorafenib or a salt thereof with 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid or a salt thereof.... Agent: Taiho Pharmaceutical Co., Ltd.

20110172183 - Method of fixing antibacterial agent article obtained by the method: wherein R1 represents a hydrocarbon group having 6 or more carbon atoms, R2 and R3 represent lower hydrocarbon groups, respectively, which hydrocarbon groups may be the same or different from each other, R4 represents a divalent lower hydrocarbon group, R5, R6 and R7 represent lower alkyl groups or lower alkoxy... Agent: Hiroshima University

20110172185 - Therapeutic drug for adult t-cell leukemia: wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2... Agent:

20110172189 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in... Agent: Pimco 2664 Limited

20110172187 - Boron-containing small molecules: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.... Agent: Anacor Pharmaceuticals, Inc.

20110172186 - Inhibitors of fatty acid amide hydrolase: The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or... Agent:

20110172188 - Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid,... Agent: Bio Modeling Systems Ou Bmsystems

20110172190 - Agents for preventing and treating disorders involving modulation of the ryanodine receptors: and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated... Agent:

20110172192 - Method and compositions for treating hematological malignancies: d

20110172191 - Thieno-pyridine derivatives as mek inhibitors: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are... Agent: Ucb Pharma S.a.

20110172193 - Pro-drugs of (e)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid: The present invention is directed to pro-drugs of (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, pharmaceutical compositions containing them and the use of said pro-drugs and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.... Agent:

20110172194 - Composition of dialysis liquid comprising crystallisation inhibitor substances: This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these... Agent:

20110172195 - Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.... Agent: Arizona Board Of Reg. On Behalf Of The Univ. Of Az

20110172196 - Pharmaceutical composition and method for treating hypogonadism: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.... Agent:

20110172197 - Dosace form for hormonal contraceptive: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units... Agent: Grunenthal Gmbh

20110172198 - Tgr5 modulators and methods of use thereof: The invention relates to compounds of Formula A: (A) or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.... Agent: Intercept Pharmaceuticals, Inc.

20110172199 - Platinum-n-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof: in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R′ is a hydrogen atom and R is a group selected... Agent: Centre National De La Recherche Scientifique

20110172200 - Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics: The present invention relates to a pharmaceutical composition with broad-spectrum of activity against class A, class C and D enzymes comprising an antibiotic and a pharmaceutically effective amount of a compound of Formula (I), compounds of Formula (I), the use of a therapeutically effective amount of one or more compounds... Agent: Lek Pharmaceuticals D. D.

20110172201 - Process for preparing a carbapenem antibiotic composition: The present invention relates to a process for preparing a carbapenem antibiotic composition. The present invention further relates to a carbapenem antibiotic composition substantially free of degradation impurities. The present invention further relates to a polymorphic form of ertapenem mono sodium designated as Form D and its preparation.... Agent: Ranbaxy Laboratories Limited

20110172202 - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with... Agent:

20110172204 - Compounds and their use: R2 represents C1-4alkyl substituted by C1-3 alkoxy; R3 represents C1-4 alkyl; W represents —(CH2)n—; W1 represents —(CH2)p—; n represents 1 or 2 or 3; p represents 1 or 2; R4 represents C1-4 alkoxy, C1-6 alkyl or halogen; and R5 represents halogen or H, provided that, when R4 represents halogen, R5... Agent: Takeda Pharmaceutical Company Limited

20110172203 - Substituted imidazopyridinyl-aminopyridine compounds: The present invention relates to substituted imidazopyridinyl-aminopyridine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl-aminopyridine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110172205 - Monocyclic amide cgrp receptor antagonists: Compounds of formula (I): wherein variables B, m, n, J, R4, Ea, Eb, Ec, Rf, RPG and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention... Agent: Merck Sharp & Dohme Corp.

20110172206 - Compositions and methods for treatment of neurodegenerative disease: Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.... Agent: The Johns Hopkins University

20110172207 - Substituted pyrazolamides and their use: The present invention relates to novel substituted pyrazolamides, methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of retroviral diseases, in humans and/or animals.... Agent: Aicuris Gmbh & Co. Kg

20110172208 - Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition: or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or the like; R4 is cyano, lower alkoxycarbonyl, carboxy or the like, which exhibit potent COMT inhibitory... Agent: Kissei Pharmaceutical Co., Ltd.

20110172209 - 3h-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of gpr81 receptor disorders: The present invention is directed to certain 3H-imidazo[4,5-b]pyridin-5-ol derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the GPR81 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds... Agent: Merck & Co., Inc.

20110172210 - Method for titrating clozapine: Method for titrating clozapine in treatment of psychotic disorders in a human patient in need of treatment with clozapine including administering once-a-day controlled release clozapine to the human patient titrating to a therapeutic dose of clozapine within a period of less than one week, or administering controlled release clozapine to... Agent: Azur Pharma Limited

20110172212 - Amine-based compound and use thereof: t

20110172211 - Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anti-convulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting... Agent:

20110172213 - Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.... Agent: Ed. Geistlich Soehne Ag Fuer Chemische Industrie

20110172214 - Use of targeted nitroxide agents in preventing, mitigating and treating radiation injury: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage... Agent:

20110172215 - Benzene sulfonamide thiazole and oxazole compounds: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent:

20110172216 - Pyrazolopyrimidine pi3k inhibitor compounds and methods of use: Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for... Agent: F. Hoffmann-la Roche Ag

20110172217 - Ring-fused morpholine derivative having pi3k-inhibiting activity: The present invention provides compounds or a pharmaceutically acceptable salt thereof which inhibit the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and are therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases,... Agent: Shionogi & Co., Ltd.

20110172218 - Cgrp antagonists: The present invention relates to novel CGRP antagonists of the general formula (I) in which U, V, X, Y, R1, R2, R3 are defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, and the hydrates of the salts, particularly the physiologically compatible salts thereof having... Agent: Boehringer Ingelheim International Gmbh

20110172219 - Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors: Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.... Agent:

20110172221 - Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof: This invention relates to novel annellated 4-(indazolyl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110172220 - Discodermolide analogues and methods of their use: 6- and 7-substituted coumarin and related 6- and 7-substituted 1H-quinolin-2-one compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the 7-substituted coumarin and related 7-substituted 1H-quinolin-2-one compounds mimic or exceed the high level of pharmacological activity of discodermolide. In other embodiments, their... Agent: The Trustees Of The University Of Pennsylvania

20110172222 - Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract: The present invention relates to the use of selective inhibitors of coagulation factor Xa, in particular of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of inflammatory conditions of the gastrointestinal tract such as inflammatory bowel disease (IBD) and celiac disease and/or disorders related to inflammatory bowel disease... Agent: Bayer Schering Pharma Aktiengesellschaft

20110172223 - Substituted aryl sulfone derivatives as calcium channel blockers: A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with,... Agent:

20110172225 - Antifungal agents: Novel derivatives of enfumafungin are disclosed herein, along with their, pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates... Agent: Scynexis, Inc.

20110172224 - Novel heterocycles: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.... Agent: Bayer Pharmaceuticals Corporation

20110172226 - Novel hydrazide containing taxane conjugates: The present invention relates to compounds of formula I or salts thereof, wherein, R1 is selected from the group consisting of hydrogen and R4; R2 is selected from the group consisting of hydrogen, acetyl and R4; R3 is selected from the group consisting of alkyl, —O-alkyl, —NH-alkyl, aryl and heterocyclyl;... Agent: Sun Pharma Advanced Research Company Ltd.

20110172227 - Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same: which are useful as selective allosteric or bitopic agonists of the M1 muscarinic receptor; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurodegenerative diseases, including Alzheimer's Disease. This abstract is intended as a scanning tool for purposes... Agent:

20110172228 - Kinase inhibitors and methods of use: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or... Agent:

20110172229 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20110172231 - 2,4- diaminopyrimidine derivatives: m

20110172230 - Urea compound or salt thereof: [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the... Agent:

20110172232 - Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders: The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-3-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.... Agent: Bayers Schering Pharma Aktiengesellschaft

20110172234 - Methods and compositions of trail-death receptor agonists/activators: This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The... Agent: University Of Maryland, Baltimore A Constituent Institution Of The University

20110172233 - Sonic hedgehog modulators: The present invention relates to relates to macrocyclic small molecule inhibitors of the Sonic Hedgehog signaling pathway, syntheses thereof, and intermediates thereto. Such small molecule modulators of the Sonic Hedgehog signaling pathway are useful in the treatment of proliferative diseases (e.g., basal cell carcinoma, Gorlin syndrome, medulloblastoma, or pancreatic cancer),... Agent:

20110172235 - Substituted triazolophthalazine derivatives: This invention relates to novel substituted triazolophthalazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering selective α5 receptor partial or full inverse agonists.... Agent: Concert Pharmaceuticals, Inc.

20110172236 - Substituted aryl sulfone derivatives as calcium channel blockers: A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with,... Agent:

20110172237 - Quinuclidine derivatives as muscarinic m3 receptor antagonists: The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for’ the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.... Agent:

20110172238 - Benzimidazole analogues for the treatment or prevention of flavivirus infections: e

20110172239 - Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed... Agent:

20110172240 - Fatty acid fumarate derivatives and their uses: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.... Agent:

20110172241 - Benzazole analogues and uses thereof: e

20110172242 - Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds: A method of treating exposure to organophosphate agents through the use of compounds comprising tetrahydroindolone and arylpiperazine moieties.... Agent:

20110172243 - Use of azaperone for reducing antibiotic usage: The present invention relates to a method for the reduction of antibiotic usage in animals through the use of orally administered azaperone.... Agent: Janssen Pharmaceutica Nv

20110172244 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, of Formula I: pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.... Agent: Irm LLC

20110172245 - Heterocyclic compound and use thereof: e

20110172246 - 1-(2-phenoxymethylphenyl)piperazine compounds: where a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing... Agent:

20110172248 - Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for... Agent:

20110172247 - Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for... Agent:

20110172249 - Method for improving absorbability of preparation, and preparation having improved absorbability: The present invention provides a method for improving absorbability of the active ingredient of an enteric polymer coated preparation, which includes using an organic acid.... Agent: Takeda Pharmaceutical Company Limted

20110172250 - Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists: Provided herein are 2H- and 13C-enriched compounds of formula (I) or (II); wherein R is as defined herein, and wherein at least one hydrogen atom, in certain embodiments, three or more hydrogen atoms, are deuterium atoms or at least one carbon atom is a carbon-13 atom. Also provided are pharmaceutical... Agent:

20110172251 - Method of treating mental disorders using of d4 and 5-ht2a antagonists, inverse agonists or partial agonists: The present invention relates to methods of treating the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability—hypersensitivity—hyperaesthesia—dissociative phenomena— . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising... Agent:

20110172252 - Triazolo[4,5-d]pyramidine derivatives and their use as purine receptor antagonists: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.... Agent: Vernalis Research Limited

20110172253 - Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines: The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.... Agent: Metaproteomics, LLC

20110172254 - Folate receptor binding conjugates of antifolates: Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating such diseases are also described.... Agent: Endocyte, Inc.

20110172255 - Condensed n-heterocyclic compounds and their use as crf receptor antagonists: The present invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).... Agent: Neurocrine Bioscienses, Inc.

20110172256 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent:

20110172257 - (poly) aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent. Formula (1) wherein: —R represents hydrogen or C1-4alkyl, —A represents CO(CH2)n or CONH(CH2)n where n=2,... Agent:

20110172258 - Indene derivatives as pharmaceutical agents: e

20110172259 - Dosage form containing oxycodone and naloxone: The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.... Agent: Euro-celtique S.a.

20110172260 - Methods of providing weight loss therapy in patients with major depression: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.... Agent: Orexigen Therapeutics, Inc.

20110172261 - Dibenzo[f,h]isoquinoline derivatives: A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection.... Agent: National Health Research Institutes

20110172262 - Compositions and methods for treating epilepsy: Compositions and methods for treating epilepsy and epileptic syndromes are described herein. The compositions and methods include therapeutically effective amounts of one or more dimebolins, or pharmaceutically acceptable salts thereof.... Agent: Biovista, Inc.

20110172263 - Indole derivatives as crth2 receptor antagonists: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.... Agent: Merck Frosst Canada Ltd

20110172264 - Nicotinic acetylcholine receptor modulators: Provided herein are novel and selective high affinity α3β4 nicotinic acetylcholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein.... Agent:

20110172265 - Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety,... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110172266 - Pyrazolo pyridine derivatives as nadph oxidase inhibitors: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Genkyotex Sa

20110172267 - Tsh receptor antagonizing tetrahydroquinoline compounds: The present invention relates the use of a compound, a pharmaceutical composition, compounds and a kit for treating or preventing disorders in a mammal responsive to TSH receptor mediated pathways, including disorders such as hyperthyroidism, Graves' disease, Graves Ophthalmopathy, Graves' associated pretibial dermopathy, nodular goitre and thyroid cancer comprising administering... Agent: N.v. Organon

20110172269 - Antioxidant combinations for use in feed rations to increase milk production and milk fat: The present invention provides a combination of antioxidants that effectively stabilize different types of fats utilized in a ruminant diet. When included in a ruminant feed ration or water source, the antioxidant combination typically increases nutrient digestion, such as fiber and protein, improves rumen fermentation, improves microbial growth, improves microbial... Agent: Novus International Inc.

20110172268 - Mechanism-based small-molecule parasite inhibitors: Methods for preventing or treating an Apicomplexan parasite infection in a patient administering to a patient in need thereof an effective amount of a compound of Formulas I-IV.... Agent: Philadelphia Health And Education Corporation D/b/a Drexel University College Of Medicine

20110172270 - 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity: 1,4-disubstituted piperidine compounds of general formula (I) wherein the substituents are defined in claim 1 that are suitable in particular as active substances in medicaments, preferably in medicaments for the regulation of neuropeptide Y receptors, particularly preferably of neuropeptide Y5 (NPY5) receptor, for the regulation of food ingestion (food intake),... Agent: Laboratorios Del Dr. Esteve S.a

20110172271 - Urinary triaosylceramide (gb3) as a marker of cardiac disease: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels... Agent: Baylor Research Institute

20110172272 - Benzisoxazoles: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent:

20110172273 - Methods of treating myelodysplastic syndromes using lenalidomide: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.... Agent:

20110172274 - Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity: t

20110172275 - Pyrrole compounds: wherein R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, R4 and R6 are each a hydrogen atom, a halogen atom or a C1-6 alkyl group optionally substituted by halogen,... Agent: Takeda Pharmaceutical Company Limited

20110172276 - Carboxamide compound and use of the same: e

20110172277 - Pirfenidone therapy and inducers of cytochrome p450: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.... Agent: Intermune, Inc.

20110172278 - Compounds and methods for modulating g protein-coupled receptors: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.... Agent: Irm LLC

20110172279 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Incyte Corporation, A Delaware Corporation

20110172281 - Anti-viral drugs for treatment of arenavirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused... Agent: Siga Technologies Inc.

20110172280 - Substituted benzimidazoles: This invention relates to novel substituted benzimidazoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound that modulates the GABAA receptor. This... Agent: Concert Pharmaceuticals, Inc.

20110172282 - Use of spiro-oxindole compounds as therapeutic agents: This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for... Agent: Xenon Pharmaceuticals Inc.

20110172283 - Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating... Agent:

20110172284 - Methods for treating spinal muscular atrophy: Described herein are methods for the identification or validation of compounds capable of causing ribosomal frameshifting and the use of said compounds to produce a stabilized SMNΔEx7 protein and treat Spinal Muscular Atrophy.... Agent:

20110172285 - Proteasome inhibitors: Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.... Agent: Nereus Pharmaceuticals, Inc.

20110172297 - Oxopiperdinyl and pyranyl sulfonamides and pharmaceutical compositions thereof: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of Formula (I): as defined in the specification. The invention is also directed to compositions containing the compounds of Formula (I) as AMPA modulators.... Agent: Pfizer Inc

20110172298 - Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol: Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol. Indication of use of erdosteine as prophylaxis for intoxications. Erdosteine can be administered per os or intravenous, using a solution obtained with sodium hydrogen carbonate and bidistilled... Agent:

20110172299 - Therapeutic substituted cyclopentanes: Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20110172300 - Novel epigallocatechin gallate trimer and alpha-glucosidase inhibitor containing epigallocatechin gallate polymer: The present invention provides an α-glucosidase inhibitor containing a novel epigallocatechin gallate trimer and an epigallocatechin gallate polymer. Decomposition of starch derived from a meal and sugar derived from a polysaccharide can be suppressed by α-glucosidase inhibitory action, thus suppressing absorption. A food and drink excellent in α-glucosidase inhibitory action... Agent: Suntory Holding Limited

20110172301 - Use of anti-oxidant compounds for muscle recovery: The present invention describes the use of a composition comprising a compound according to formula (1) to retain or restore muscle health: formula (1) wherein: R can be H, OH or CH3O; R1 can be H, (CH2)nOR2 wherein: n is 1, 2 or 3 R2 is H, COCH3 or formula... Agent: DsmIPAssets B.v.

20110172302 - Methods of treating meibomian gland dysfunction: The present invention includes methods for treating Meibomian gland dysfunctions. The invention also includes methods for improving tear lipid composition, for treating abnormal Meibomian gland secretion and for normalizing Meibomian gland secretions.... Agent:

20110172303 - Deacetylase inhibitors and uses thereof: The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacetylase inhibitors) and may be useful in the treatment of proliferative diseases such as cancer. In particular, the inventive compounds are HDAC6 inhibitors. The invention also provide... Agent: President And Fellows Of Harvard College

20110172304 - Sex attractant of white peach scale and attraction method: Provided is an attractant of white peach scale capable of simplifying the synthesis of a sex pheromone of white peach scale and suppressing attraction of a parasitoid wasp which is a natural enemy of the white peach scale. More specifically, provided is a sex attractant of white peach scale comprising... Agent: Shin-etsu Chemical Co., Ltd.

20110172305 - Endocannabinoids for enhancing growth and development in infants: The present invention relates to a method for promoting infant feeding, growth or development comprising administering to an infant a formula or a pharmaceutical composition comprising an endocannabinoid in an amount sufficient to promote feeding, growth or development. The present invention also relates to an infant formula comprising an enhanced... Agent:

20110172306 - Creatine ester pronutrient compounds and formulations: The present invention describes a method for providing creatine to an animal, which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.... Agent:

20110172307 - Antimicrobial compositions for use on food products: The present invention relates to antimicrobial compositions, and specifically antimicrobial compositions that are useful at sanitizing food products. The compositions of the present invention include octanoic acid, an acidulant, a coupling agent, an optional buffer, and water. The compositions of the present invention are composed of GRAS or food additive... Agent: Ecolab Inc.

20110172308 - Antagonsim of pgf2a receptor to treat hyertension characterized by activation of the renin-angiotensin-aldosterone system: The present invention relates to methods for identifying candidate therapeutics for hypertension. The invention further provides a method for treating hypertension and/or decreasing atherogenesis by administration of an inhibitor of PGF2α receptor.... Agent: The Trustees Of The University Of Pennsylvania

20110172309 - Galenic formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active incredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.... Agent:

20110172310 - Di-fluoro containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Virobay, Inc.

20110172311 - Compounds for treating human papillomavirus: Methods and compositions for treating human papillomavirus infections are described.... Agent:

20110172312 - Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones: The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.... Agent:

20110172313 - Image quality in the eye: Pharmaceutical compositions or dietary supplements are provided containing lutein, zeaxanthin, or mixtures thereof in amounts effective to improve image quality in the human eye. Methods are also provided for reducing higher order wavefront aberrations in the human eye to improve image quality by administering to a person in need of... Agent: DsmIPAssets B.v.

20110172314 - Amphiphilic branched polymers and their use as emulsifiers: The present invention relates to amphiphilic branched copolymers, methods for their preparation, emulsions comprising such copolymers and their use as emulsifiers. The polymers are responsive by nature, by forming non-covalent bonds between monomer residues upon applying external stimuli. In a preferred embodiment of the copolymer, the copolymer can be used... Agent: Unilever N.v.

20110172315 - Composition for cryopreservation of cells and tissues: A composition for cryopreservation of cells and tissues of human and other animals in a safe manner without using toxic substances such as DMSO, as well as for freeze preserving or freeze-drying of foods and pharmaceuticals. In examples, ε-poly-L-lysine is reacted with succinic anhydride so that 60% or more of... Agent: Bio Verde. Inc.

  
07/07/2011 > patent applications in patent subcategories. category listing

20110166059 - Means and methods for evaluating a therapy with a p38 map kinase inhibitor: The present invention relates to a method for determining whether therapy with a p38 MAP kinase inhibitor is potentially beneficial or potentially contraindicated for a subject suffering from a p38-mediated condition comprising measuring in a sample obtained from the subject the presence of at least one chromatin remodelling gene and/or... Agent:

20110166058 - Organic compositions to treat hsf1-related diseases: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.... Agent: Novartis Ag

20110166060 - Tympanic membrane permeating ear drops and uses thereof: The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis... Agent: Children's Medical Center Corporation

20110166061 - Long lasting fusion peptide inhibitors for hiv infection: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV),... Agent: Conjuchem Biotechnologies, Inc.

20110166062 - Gip-based mixed agonists for treatment of metabolic disorders and obesity: Glucagon peptides that exhibit GIP agonist activity in addition to glucagon and/or GLP-I activity are provided. Pharmaceutical compositions comprising such glucagon peptides and therapeutic methods of using such peptides are also provided.... Agent: Indiana University Research And Technology Corporation

20110166063 - Polymer conjugates of therapeutic peptides: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20110166064 - Halogen-stabilized insulin: An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin... Agent: Case Western Reserve University

20110166065 - Modulation of glucose-6-phosphatase translocase expression: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders.... Agent: Isis Pharmaceuticals, Inc.

20110166066 - Catestatin (cst) and its variants for treatment of cardiovascular and metabolic disorders: Circulating levels of catestatin (Cts: human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pre-treatment of Chga-null mice with Cts prevents blood pressure elevation, indicating a direct role of Cts in preventing hypertension.... Agent:

20110166067 - Methods for inhibition of scarring: The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which... Agent: Renovo Limited

20110166068 - Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or pro-phylaxis of heart failure: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any... Agent: Acorda Therapeutics, Inc.

20110166069 - Compositions and methods for stimulating gastrointestinal motility: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.... Agent:

20110166070 - Method of preventing premature delivery: The disclosure pertains to methods of decreasing the risk of premature birth and miscarriage in human females. Particularly, the disclosure provides methods of reducing cervical dialation and preterm delivery by administration of relaxin.... Agent:

20110166071 - Method for synthesizing thymosins: The invention relates to a method for obtaining thymosins and/or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form,... Agent:

20110166072 - Polypeptides selective for avb3 integrin, including pegylated polypeptides, and pharmaceutical uses thereof: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective αvβ3 integrin antagonists for treatment and prevention of αvβ3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to... Agent:

20110166073 - Anti-hypertensive agent: The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6),... Agent: Mg Pharma Inc.

20110166074 - Cln2 treatment of alzheimer's disease: A method of treating Alzheimer's Disease may include administering to a subject in need of such treatment a CLN2 therapeutic having beta-amyloid degradation activity.... Agent: Cornell Research Foundation, Inc.

20110166075 - Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.... Agent: The Regents Of The University Of California

20110166076 - Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases: The present invention relates to superantigen-specificantigen-binding proteins comprising an immunoglobulin-derived variable domain that comprises a complete antigen binding site for an epitope on the superantigen in a single polypeptide chain. The antigen-binding proteins of the invention may be used in the treatment skin diseases. The antigen-binding proteins of the invention... Agent: BacIPB.v.

20110166078 - Oligosaccharide compounds for use in mobilising stem cells: A compound of the following formula or a salt, solvate or formula (I) and a pharmaceutical composition containing said compound. It concerns also its use in the treatment of cancer and/or of pathological angiogenesis and/or in promoting the mobilisation of stem cells, in particular hematopoietic stem cells.... Agent: Endotis Pharma

20110166077 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy: The present invention provides the use of acryloyl distamycin derivatives, in particular α-bromo- or α-chloro-acryloyl distamycin derivatives, in combination with radiotherapy, for the treatment of tumors.... Agent: Pharmacia Italia S.p.a.

20110166079 - Methods of treating cancer with apoe peptides: Methods of treating chronic lympocytic leukemia, chronic myelogenous leukemia, and breast cancer in a subject by administering an ApoE peptide are disclosed.... Agent: Cognosci, Inc.

20110166080 - Deuterated cyclosporine analogs and methods of making the same: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporin and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution... Agent: Isotechnika, Inc.

20110166081 - Alpha-dystroglycan as a protein therapeutic: Disclosed is alpha-dystroglycan protein (alpha-DG) in glycosylated and functional form. The disclosed alpha-DG binds to the basal lamina and to the sarcolemma of muscle fibers and may be injected into muscle and incorporated into muscle fibers in order to restore membrane integrity where the muscle fibers comprise a dysfunctional alpha-DG... Agent: University Of Iowa Research Foundation

20110166082 - Antisense composition and method for treating muscle atrophy: A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has... Agent: Avi Biopharma, Inc.

20110166084 - Controlled release composition and method of producing the same: A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a... Agent: Takeda Pharmaceutical Company Limited

20110166083 - Peptide analogues, particularly for the treatment of chronic pain: The use is claimed of opioid peptides with a novel structure, which in addition to the pharmacophore contain structural elements that interact with neurotensisn receptors. Due to the synergistic interaction with the additional element, an augmented analgesic activity is obtained, capable of being used for an extended period due to... Agent:

20110166085 - Composition comprising carbohydrates and peptides which comprise tryptophan: An edible composition comprising peptides rich in tryptophan, which edible composition further comprises a rapidly available glucose composition and a slowly available glucose composition.... Agent:

20110166086 - Flavor improving agent: Disclosed is a flavor improving agent that is a fraction derived from fruit juice or squeeze. A fraction wherein the amount of substance ratio between polyphenols and saccharides, the latter after acid hydrolysis of the fraction, (polyphenol/saccharide) is 0.1-10, and even more preferably, wherein the amount of substance ratio of... Agent:

20110166087 - Pharmaceutical composition for use in treating sexually transmitted infections: The present invention relates to a solid oral pharmaceutical composition comprising fluconazole, tinidazole and clindamycin or a pharmaceutically acceptable salt thereof, wherein the content of pharmaceutically acceptable excipients is significantly lower than the content of the active principles, the use of said composition for oral administration with therapeutic activity for... Agent:

20110166088 - Benzothiazoles and aza-analogues thereof use as antibacterial agents: The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci,... Agent: Ranbaxy Laboratories Limited

20110166089 - Solution for tissue adhesion prevention and method for tissue adhesion prevention: The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the... Agent: The University Of Tokyo

20110166090 - 18-membered macrocycles and analogs thereof: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.... Agent:

20110166091 - Compositions containing piperacillin and tazobactam useful for injection: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that... Agent: Wyeth Holdings Corporation

20110166092 - Dosing methods for treating disease: The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: Formula (I) 5-amino-3-(2′-Q-acetyl-3′-deoxy-β-D-ri-bofuranosyl)-3H-thia-zolo[4,5-d]pyrimidin-2-one... Agent: Anadys Pharmaceuticals, Inc.

20110166203 - Anti-hepatitis c virus composition: The present invention provides an anti-hepatitis C virus composition that includes a substance that suppresses the expression or function of a PA28γ gene, a method for preventing hepatitis C viral infection or suppressing hepatitis C virus growth that includes the step of administering the composition to a subject, and a... Agent: Osaka University

20110166197 - Antisense modulation of amyloid beta protein expression: Antisense nucleic acids, compositions and methods are provided for modulating the expression of an amyloid beta protein (AβP) portion of the amyloid precursor protein (APP) coding sequence. The compositions comprise antisense nucleic acids targeted to nucleic acids encoding amyloid precursor protein. Methods of using these nucleic acids for modulation of... Agent: Edunn Biotechnology, Inc.

20110166202 - Formoterol/steroid bronchodilating compositions and methods of use thereof: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided... Agent: Dey, L.p.

20110166200 - Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer: The present invention provides compositions and methods for predicting the hypoxia response in tumor cells, methods for predicting the likelihood of cancer metastasis, and methods for inhibiting tumor cell proliferation using a microRNA comprising miR-210.... Agent:

20110166201 - Mirnas as therapeutic targets in cancer: MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3′ untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit,... Agent:

20110166204 - Oligonucleotides targeting human endogenous retrovirus 9 (erv-9) long terminal repeat (ltr) and methods of use: Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding strand or non-coding strand of ERV-9 LTR. It is disclosed herein that ERV-9 LTR oligonucleotides inhibit the proliferation of cancer cells, including breast cancer, liver... Agent:

20110166198 - Rna compositions for modulating immune response: This invention features modified iRNA agents that modulate an immune response, methods of making and identifying iRNA agents that modulate an immune response, and methods of using the iRNA agents to modulate an immune response.... Agent: Alnylam Pharmaceuticals, Inc.

20110166199 - Rnai compound targeted to thrombospondin-1 and applications thereof: The present invention relates to an RNAi compound and an expression plasmid for inhibiting expression of Thrombospondin-1, which comprises a target sequence selected from Thrombospondin-1 gene. The present invention also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of... Agent: National Cheng Kung University

20110166205 - Substituted alpha-l-bicyclic nucleosides: The present disclosure describes substituted α-L-bicyclic nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, substituted α-L-bicyclic nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including binding affinity. In some embodiments, the oligomeric... Agent:

20110166196 - Treatment and prophylaxis of epilepsy and febrile seizures: Provided are methods for treatment and prophylaxis of convulsive disorders and seizures, such as epilepsy and febrile seizures, by modulating TRPV1 channel activation.... Agent:

20110166209 - Compositions and methods for ameliorating myosin viia defects: The invention provides compositions and methods for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including providing vectors for myosin VIIa expression and formulations comprising them, and methods of using them, for treating human retinitis pigmentosa (or retinal degeneration), and blindness and deafness such as that found in Usher... Agent: The Regents Of The University Of California

20110166212 - Gene expression and pain: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.... Agent: Adynxx, Inc.

20110166210 - Improved expression of il-12 family heterodimers: The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer... Agent: The Govt. Of The U.s.a. As Represented By The Sec. Of The Dept. Of Health And Human Services

20110166211 - Lyophilized dna formulations for enhanced expression of plasmid dna: The present invention provides for a method of treating or preventing ischemic or liver disease in a subject by administering a composition reconstituted from a lyophilized hepatocyte growth factor (HGF) DNA formulation, where the DNA formulation comprises an HGF plasmid DNA, salt and a carbohydrate. The invention further provides for... Agent: Viromed Co., Ltd.

20110166213 - Method for obtaining oligonucleotide aptamers and uses thereof: The present invention relates to a method for obtaining nucleic acid aptamers that bind to cancer cell-surface epitopes, to the aptamers generated using this method and their use for therapeutic, diagnostic and prognostic purposes.... Agent: Consiglio Nazionale Delle Ricerche

20110166208 - Nucleotide and amino acid sequences for calmodulin protein methyltransferase: The present invention provides nucleic acid and amino acid sequences for calmodulin protein methyltransferase. The present invention also provides diagnostic tools and methods of using the present invention to diagnose and treat diseases and conditions linked with calmodulin methyltransferase, as well as methylated calmodulin intermediates.... Agent: University Of Kentucky

20110166206 - Ubiquilin regulation of presenilin endoproteolysis, and suppression of polyglutamine-induced toxicity in cells: Use of ubiquilin is described, including utilization for reducing fragmentation of presenilin 1 and 2 and to modulate γ-secretase components, Pen-2 and Nicastrin, as well as utilization for inducing increased levels of ubiquilin to reduce aggregation of polyglutamine expansion proteins known to cause cell toxicity and cell death in subjects... Agent: University Of Maryland Biotechnology Institute

20110166207 - Use of aav integration efficiency element for mediating site-specific integration of a transcription unit: The invention provides an expression construct comprising a nucleic acid sequence encoding an adeno-associated virus integration efficiency element (AAV IEE), wherein the expression construct is substantially devoid of AAV inverted terminal repeats (AAV ITRs). Such an expression construct site-specifically integrates into a host cell chromosome when provided to a host... Agent: Cornell Research Foundation, Inc.

20110166094 - Agonists of a2a adenosine receptors for treating recurrent tumor growth: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).... Agent: Pgxhealth, L.L.C.

20110166093 - Use of adenosine receptor agonists in therapy: Use of compounds of formula: (I) wherein R is C1-4 alkoxy and X is H or OH; for the prevention, treatment, or amelioration of cancer, inflammation, auto-immune disease, ischemia-reperfusion injury, epilepsy, sepsis, septic shock, neurodegeneration (including Alzheimer's Disease), muscle fatigue or muscle cramp is described. The compounds are effective at... Agent:

20110166095 - Cancer platinum resistance detection and sensitization method: The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody... Agent: University Of South Florida

20110166096 - Uracil derivatives and use thereof: e

20110166097 - Taxane compounds for treating eye disease: The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a taxane-cobalamin bioconjugate or another taxane compound to a subject to treat the eye disease. In one embodiment, the bioconjugate can be dissolved in an aqueous solution prior to administration.... Agent: Osiris Therapeutics, Inc.

20110166098 - Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease: The present invention is related to a hyaluronic acid formulation including a mixture of hyluronic acids having different weight-average molecular weight and different rheological, tissue scaffold and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold and treating time on the treatment and... Agent:

20110166100 - Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease: The present invention is related to a hyaluronic acid formulation including a mixture of hyaluronic acids having different weight-average molecular weight and different rheological, tissue scaffold, insulation and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold, insulation and treating time on the... Agent:

20110166099 - Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer: The present invention is related to a hyaluronic acid composition with a binary mixture of hyaluronic acids having mainly different weight-average molecular weight and then different rheological, scaffold and degradation properties in aqueous solution. The resulted compositions have demonstrated an optimal balance between adhesion, tissue scaffold and treating time to... Agent:

20110166101 - Microparticles: A substantially porous, micro-particle comprising therapeutically effective amounts of tretinoin and ethyl cellulose... Agent: Sun Pharma Advanced Research Company Limited

20110166102 - Novel 2-substituted benzimidazoles as selective androgen receptor modulators (sarms): The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent:

20110166103 - Boron-containing small molecules: This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20110166104 - Boron-containing small molecules: This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20110166105 - Antimicrobial wash and carrier solutions and uses thereof: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.... Agent: Teva Animal Health, Inc.

20110166106 - Artemisinin and derivatives thereof as antivirals: Methods to treat various herpes viral infections using the natural product artemisinin and derivatives of that compound are described. The methods are especially applicable for treatment of conditions associated with HHV-6, and are also applicable to the treatment of conditions that are induced or exacerbated by an HHV-6 infection or... Agent:

20110166107 - Methods and kits for detecting risk factors for development of jaw osteonecrosis and methods of treatment thereof: Methods of and kits for determining the pharmacogenetic, pharmacokinetic and cellular basis of bisphosphonate-induced osteonecrosis of the jaw (BONJ) involve associating particular proteins and particular single nucleotide polymorphisms with a risk for developing BONJ after receiving bisphosphonate treatment. Methods and kits for identifying the genetic basis for a patient's predisposition... Agent: University Of Florida Research Foundation Inc.

20110166108 - Methods of use related to xerostomia: The present invention relates to new uses of thermally stable, crystalline S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by radiation treatment. In particular, the invention provides a method for treating or preventing xerostomia associated with the administration of radiation treatment of head and... Agent: Medimmune, LLC.

20110166109 - Synergistic active compound combinations comprising phenyltriazoles: e

20110166110 - Fused ring azadecalin glucocorticoid receptor modulators: The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Corcept Therapeutics, Inc.

20110166111 - Composition for the reduction of drip losses in pork: 25-hydroxyvitamin D3 has been found to reduce drip losses in swine carcasses. Feed containing about 25-75 μg/kg 25-hydroxyvitamin D3 improves the water holding capacity of meats, including pork.... Agent:

20110166112 - Method for stimulating platelet production: Provided are methods for increasing platelet response in a subject at risk for bleeding due at least in part to a low platelet count by administering to a subject with a low platelet count an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridine-2-yl)piperidine-4-carboxylic acid.... Agent: Eisai, Inc.

20110166114 - Method for treating snoring and sleep apnea with leukotriene antagonists: A method of treating snoring and/or sleep apnea comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist.... Agent: University Of Louisville Research Foundation

20110166113 - Method for treating the hyperpigmentation of pathological scars: Dermatological medicament compositions contain a combination of hydroquinone, fluocinolone acetonide and tretinoin and are useful for the treatment of the hyperpigmentation of pathological scars, namely, hypertrophic scars and keloidal scars.... Agent: Galderma S.a.

20110166115 - Use of mifepristone for the treatment of amyotrophic lateral sclerosis: The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).... Agent: Corcept Therapeutics, Inc.

20110166118 - New trinem antibiotics and inhibitors of beta-lactamases: The present invention relates to a compound of Formula (I) in particular compounds of formula (Ia), the use of a therapeutically effective amount of one or more compounds of formula (I) or (Ia) as a broad-spectrum antibiotic and the use of a pharmaceutical composition comprising said compounds for the treatment... Agent: Lek Pharmaceuticals D.d.

20110166119 - Synergistic combinations of aztreonam with the carbapenems meropenem and ertapenem: A pharmaceutical composition comprising carbapenem and Aztreonam each in the dosage range of about 0.25 g to 0.75 g and pharmaceutically acceptable excipients for the prevention and treatment of infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae or MRSA (Methicillin Resistant Staphylococcus aureus).... Agent: Glade Organics Private Limited

20110166121 - Fused heterocyclic compound: The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.... Agent: Lg Life Sciences Ltd.

20110166122 - Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors: Compounds of Formula (I): in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.... Agent:

20110166120 - Sulfonyl amide derivatives for the treatment of abnormal cell growth: wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth... Agent: Pfizer Inc.

20110166116 - New compounds, pharmaceutical composition and methods relating thereto: e

20110166117 - Novel compounds: The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent:

20110166123 - Novel compositions and methods of use: Described herein are novel enzyme inhibitors. In some embodiments the enzyme inhibitors are integrase inhibitors, particularly HIV integrase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV... Agent: Aardea Biosciences, Inc.

20110166124 - Tricyclic spirocycle derivatives and methods of use: The present invention relates to novel Tricyclic Spirocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Spirocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an... Agent:

20110166125 - Substituted amides, manufacturing and use thereof as medicaments: The present invention relates to new substituted prolinamides of general formula (I) wherein D, Y, A, B, R3, R4 and R5 are defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic... Agent: Boehringer Ingelheim International Gmbh

20110166126 - Compositions and methods for modulating endophthalmitis using fluoroquinolones: Compositions for modulating endophthalmitis comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating endophthalmitis comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating post-operative endophthalmitis, post-traumatic endophthalmitis, non-infectious endophthalmitis, panophthalmitis, hematogenous endophthalmitis, or combinations thereof.... Agent:

20110166127 - Substituted benzo-pyrimido-tetrazolo-diazepine compounds: The present invention relates to substituted benzo-pyrimido-tetrazolo-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-pyrimido-tetrazolo-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110166128 - Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders: The present invention provides prodrug compounds of diaryldiazepine drug compounds.... Agent: Alkermes, Inc.

20110166129 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a... Agent:

20110166130 - Novel potassium channel blockers and uses thereof: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis,... Agent: Bionomics Limited

20110166131 - Substituted pyrrolidine derivative: A quinolone antibacterial compound, or a salt or hydrate of the compound, for the treatment of infectious diseases, which exhibit potent antibacterial activity and higher selective toxicity against Gram-positive and Gram-negative bacteria, which do not cause side effects (e.g., convulsion), which exhibit higher safety, and which has a structure of... Agent: Daiichi Pharmaceutical Co., Ltd.

20110166132 - Gamma secretase modulators: The present invention provides compounds that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.... Agent: Amgen Inc.

20110166133 - Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or... Agent: Irm LLC

20110166134 - Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease: A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.... Agent: Genzyme Corporation

20110166135 - Aromatic nitrogen-containing 6-membered ring compounds and their use: The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity. The present invention relates to an aromatic nitrogen-containing 6-membered ring compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compounds for PDE10... Agent:

20110166136 - Calcium ion channel modulators & uses thereof: e

20110166137 - Substituted naphthalenyl-pyrimidine compounds: The present invention relates to substituted naphthalenyl-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted naphthalenyl-pyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110166138 - Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors: Disclosed are compounds and compositions that inhibit the action of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), methods of inhibiting FAAH and MGL, methods of modulating cannabinoid receptors, and methods of treating various disorders related to modulation of cannabinoid receptors.... Agent:

20110166139 - Pyridine compounds: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans... Agent: Astrazeneca Ab

20110166140 - Novel sulphonylpyrroles: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.... Agent:

20110166141 - Cathepsin s inhibitors: Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.... Agent: National Health Research Institutes

20110166142 - 2-substituted isoflavonoid compounds, medicaments and uses: 2-Substituted isoflavonoid compounds and pharmaceutical compositions containing same are useful as anti-inflammatory agents and antioxidants and for the treatment of related diseases and conditions.... Agent:

20110166143 - Heterocyclic compounds as pesticides: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.... Agent: Bayer Cropscience Ag

20110166144 - Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same: The present disclosure is directed to pyrimidotriazinediones and pyrimidopyrimidinediones having a formula (I), (II), or (III), or a mixture or pharmaceutically acceptable salt or hydrate thereof, and to methods of treating cancer comprising administering the same.... Agent: The Regents Of The University Of Michigan

20110166146 - Imidazo[1,2-a]pyridine compounds: Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.... Agent: Sunovion Pharmaceuticals Inc.

20110166145 - Stabilization of hypoxia inducible factor (hif) alpha: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.... Agent: Fibrogen, Inc.

20110166150 - Anhydrous crystal form of ovrepitant maleate: The invention relates to anhydrous crystalline orvepitant maleate (Form 1), pharmaceutical formulations comprising the same, its use in therapy and processes for preparing the same.... Agent: Glaxo Group Limited

20110166151 - Glucocorticoid receptor agonist comprising 1,2,3,4-tetrahydroquinoxaline derivatives containing phenyl group having sulfonic acid ester structure introduced therein as substituent: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as... Agent: Santen Pharmaceutical Co., Ltd.

20110166152 - Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heteroaromatic compounds of structural formula (I) are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic... Agent:

20110166147 - Imidazopyrazine compounds: Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.... Agent:

20110166149 - Pteridine derivatives for treating respiratory disease: The invention provides methods and compositions for treating asthma and/or COPD. For example, provided herein are compositions that include a kinase inhibiting agent such as 6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine or pharmaceutically acceptable salts thereof; and a surfactant.... Agent: Targegen Inc.

20110166148 - Treatment of inflammation using alpha 7 receptor-binding cholinergic agonists: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is... Agent: The Feinstein Institute For Medical Research

20110166153 - Protein kinase targeted therapeutics: The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream... Agent: Northwestern University

20110166154 - Identification of predictive markers of response to dasatinib in human colon cancer: Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could... Agent: Bristol-myers Squibb Company

20110166155 - Substituted isoindolones and their use as metabotropic glutamate receptor potentiators: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use... Agent:

20110166156 - Prodrugs for the treatment of schizophrenia and bipolar disease: Compounds of Formula I and Formula II and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed.... Agent: Alkermes, Inc.

20110166157 - 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions,... Agent: Albireo Ab

20110166159 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20110166160 - Pyrazinone modulator of corticotropin-releasing factor receptor activity: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.... Agent: Bristol-myers Squibb Company

20110166158 - Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for... Agent:

20110166161 - Heterocyclic carboxamide compounds: This invention relates to novel heterocyclic carboxamide derivatives and salts thereof. More particularly, it relates to novel heterocyclic carboxamide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention... Agent: Astellas Pharma Inc.

20110166162 - 1,2-benzisothiazole compounds useful for combating animal pests: as well as to the N-oxides and salts thereof. These compounds are useful for combating animal pests. The invention also relates to a process for the preparation of these compounds and to intermediate compounds used in said process. The invention further relates to a method for controlling animal pests by... Agent: Basf Se

20110166163 - Substituted furopyrimidines and use thereof: The present application relates to novel substituted furopyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110166164 - Thiazolo[5,4-d] pyrimidines and their use as agrochemicals: The present disclosure relates to thiazolo[5,4-d]pyrimidines and their use as agrochemicals and animal health products.... Agent: Dow Agrosciences LLC

20110166165 - Bicyclic heterocycle derivatives and use thereof as gpr119 modulators: The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR)... Agent: Schering Corporation

20110166166 - Methods for detection of biological substances: Methods and compositions are provided for detection of biological substances in nasal specimen.... Agent:

20110166167 - Bicyclic heterocycle derivatives and methods of use thereof: The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR)... Agent: Schering Corporation

20110166168 - Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments: The present invention relates to sulphone-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110166169 - Novel hsp90 inhibitory carbazole derivatives, compositions containing same and use thereof: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R′1; R is selected from the group comprising Formula (A′), (B), (C), (D), or (E), with R1 and/or R′1 selected from H, halogen, CF3,... Agent: Sanofi-aventis

20110166170 - Synthesis of avrainvillamide, stephacidin b, and analogues thereof: The syntheses of the natural products, avrainvillamide and stephacidin B, are provided. The α,β-unsaturated nitrone functionality of avrainvillamide and its 3-alkylidene-3H-indole 1-oxide core is shown to covalently and reversibly bond to heteroatom-based nucleophiles. This capability may allow these molecules to bind active site nucleophiles and may provide the basis for... Agent: President And Fellows Of Harvard College

20110166171 - Sustained release monoeximic formulations of opioid and nonopioid analgesics: The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.... Agent: Abbott Laboratories

20110166172 - Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof: Rapalogs of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and preparation methods and uses thereof. The rapalogs have the structure of formula I and can be used as an anti-tumor medicament. Comparing with rapamycin, the rapalogs of the present invention exhibit enhanced water solubility, and improved pharmacological and pharmacokinetic properties... Agent: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

20110166173 - 3,5-disubstututed 1h-pyrrolo [2,3-b] pyridines as jnk inhibitors: The present invention provides novel compounds of forumula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.... Agent: Eisai Co., Ltd.

20110166175 - 7-azaindole derivatives: Novel 7-azaindole derivatives of the formula (I), in which U, L, R, Y, X1, X2 and X3 have the meanings indicated in Claim 1), are kinase inhibitors and can be used for the treatment of diseases and conditions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110166174 - Compounds modulating c-kit and c-fms activity and uses therefor: Compounds active on the receptor protein tyrosine kinases c-kit and c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or condition and c-fms-mediated diseases or condition, and methods for the use thereof.... Agent: Plexxikon, Inc.

20110166176 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.... Agent: Irm LLC

20110166177 - Bis-quaternary ammonium salts as pain modulating agents: Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.... Agent: University Of Kentucky Research Foundation

20110166178 - Methods for treating anemia using inhibitors of hypoxia-inducible factor (hif) hydroxylase: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.... Agent: Fibrogen, Inc.

20110166179 - Antibacterial quinoline derivatives: a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvateas thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the... Agent:

20110166180 - Method for treatment of bone diseases and fractures: Described herein are compounds, compositions, and methods useful for treating bone diseases or defects. Also described herein are compounds, compositions and methods for treating bone diseases or defects by inhibiting phosphatase complexes.... Agent:

20110166181 - Guanidine compounds as anesthetics and for treatment of nervous system disorders: s

20110166182 - Selective estrogen receptor modulator for the treatment of osteoarthritis: The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.... Agent: Eli Lilly And Company

20110166183 - Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium: A process for preparing esomeprazole sodium comprises the steps of providing a solution of esomeprazole sodium in a solvent constituted mainly of methanol or only of methanol; and carrying out precipitation or crystallisation of esomeprazole sodium from said solution. Esomeprazole sodium is preferably obtained from pure form of neutral racemate... Agent:

20110166184 - Insecticidal compounds: A compound of formula (I): wherein A1, A2, A3, A4, A1′, A2′, A3′, A4′, A5′, A6′, G1, R1, R2, R3, R4, R5a and R5b are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula... Agent: Syngenta Crop Protection LLC

20110166185 - Disease risk factors and methods of use: Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant... Agent: Zinfandel Pharmaceuticals, Inc.

20110166186 - Methods of administering pirfenidone therapy: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.... Agent: Intermune, Inc.

20110166187 - Methods of using sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent:

20110166188 - Methods of using sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent:

20110166189 - Methods of using sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent:

20110166190 - Methods of treating mammals with eustachian tube dysfunctions: The invention relates to methods of medically treating mammals with Eustachian tube dysfunctions, such as Ménière's disease, vertigo, Otitis Media (including Otitis Media with Effusion (OME), Acute Otitis Media (AOM) and Aerotitis Media (AM)) as well as other disorders which are characterized by ET dysfunction.... Agent:

20110166191 - 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer: 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and derivatives thereof are provided for use as dual inhibitors of the Raf/MEK/ERK and PI3K/Akt pathways and for use in the treatment of cancer.... Agent:

20110166192 - Process for charging a polymeric product with attribute imparting agent(s): The invention relates to a process for charging a polymeric product with attribute imparting agent(s) to the polymeric product prepared by the process and to a composition for preparing the polymeric product capable of retaining the acquired attributes for a long period of time.... Agent: Aditya Birla Science & Technology Co. Ltd.

20110166193 - Insecticidal compounds: A compound of Formula (I): where A1, A2, A3, A4, A5, A6, G1, L, R1, R2, R3, R4, Y1, Y2 and Y3 are as defined in claim 1; or a sail or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to... Agent: Syngenta Crop Protection LLC

20110166194 - Asenapine prodrugs: c

20110166195 - Method for the formation of megamitochondria: The present invention relates to an in-vitro method for the formation of megamitochondria in cells, wherein the cells are grown in a suitable fermentation medium acidulated with lactic acid to pH values between 5.3 and 6.7. The invention further concerns H+ ionophores, ionophores which catalyze the electroneutral exchange of K+... Agent: Universitat Leipzig

20110166214 - Methods and compositions for delivery of taxanes in stable oil-in-water emulsions: The present invention provides methods and compositions for delivery of taxanes in stable oil-in-water emulsion. The inventive emulsion formulation includes an oil phase, aqueous and emulsifier phases. The oil portion includes all or substantial amount of taxane, vegetable oil and medium chain triglycerides; aqueous phase includes an emulsion stabilizer; emulsifier... Agent: Innopharma, LLC

20110166215 - Methods of improving the pharmacokinetics of doxepin: Methods of improving the pharmacokinetics of doxepin in a patient.... Agent: Somaxon Pharmaceuticals, Inc.

20110166216 - Compositions and methods for inhibiting growth and metastasis of melanoma: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or... Agent: Burnham Institute For Medical Research

20110166217 - Pharmaceutical composition for prevention and/or treatment of bone loss: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.... Agent:

20110166218 - Methods for micronization of hydrophobic drugs: The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use.... Agent:

20110166219 - Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin: The present invention refers to a method for treating cancerous or precancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.... Agent: Medigene Ag

20110166220 - Dronedarone for the prevention of permanent atrial fibrillation: Methods of using dronedarone in the prevention of permanent atrial fibrillation.... Agent: Sanofi-aventis

20110166221 - Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion: Methods of using dronedarone in the prevention of cardioversion.... Agent: Sanofi-aventis

20110166222 - Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same: A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the... Agent:

20110166223 - Methods of inhibiting fgfr3 signaling: Novel inhibitors of FGFR3 signaling having a structure shown as Formula 1 and a method of inhibiting FGFR3 signaling by administering a quantity of the inhibitor, or pharmaceutical equivalent, analog and/or salt thereof, to a mammal are disclosed. Additionally, the inhibitor may be used for treating one or more conditions... Agent: Cedars-sinai Medical Center

20110166224 - Diacylglycerol rich fats, oils and functional foods: Disclosed is a fat or oil useful for cooking applications which includes from 10 to 90% by weight diacylglycerols, and has a SFI of at least 15% at room temperature. In particular embodiments, the fat or oil is derived from palm oil, palm kernel oil, coconut oil, sunflower oil, soybean... Agent:

20110166225 - Oral liquid compositions of rhein or diacerein: The invention relates to liquid pharmaceutical compositions for oral administration comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions.... Agent:

20110166226 - Process for obtaining an extract rich in rosmarinic acid (ra) from the plant origanum vulgare and its use for the treatment of diabetes: e

20110166227 - Balanced myristate- and laurate-containing edible oil: Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition... Agent: Brandeis University

20110166228 - Composition: wherein R1 and R2 are the same or different and are chosen from a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a... Agent:

20110166229 - Prevention of psychotic disorders and/or treatment of psychotic symptoms: The present invention relates to methods of preventing a psychotic disorder in a subject in need of intervention including administering to the subject a composition including EPA (eicosapentanoic acid) and DHA (docosahexaenoic acid). Methods of treating pre-psychotic symptoms in a subject, including administering to the subject a composition including EPA... Agent: Orygen Research Centre

20110166231 - Method of treating a human being for a class of metabolic defects and energy production disorders: The invention involves various embodiments of a method for treating a human being for a condition associated with (1) a clinical state of impairment of carnitine or carnitine esters, or decreased fatty acid metabolism, (2) low energy production or lower ATP production, (3) clinical hyperammonemia, and (4) clinically high pyruvate... Agent:

20110166230 - Method of treating a human being for a class of neurological defects and seizure disorders: The invention involves various embodiments of a method for treating a human being for a condition associated with (1) seizures, myoclonic seizures, epilepsy, refractory epilepsy, hyperkinetic movements or tremors of hands or feet, (2) a state of ataxia, (3) accumulation of neuronal autofluorescent storage bodies in lysosomes or neurons, or... Agent:

20110166232 - Enhancement of urogenital function: A method of treating nocturia in a human individual includes administering dosages of creatine to the individual; and reducing the dosages of creatine to the individual responsive to an increase in difficulty of the individual to initiate urination. Another example method includes reducing the dosages of creatine to the individual... Agent:

20110166233 - Compounds for the treatment of metabolic disorders: wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from... Agent: Wellstat Therapeutics Corporation

20110166234 - Medicinal product and treatment: The use of paracetamol and ibuprofen in the preparation of a medicament for treating osteoarthritis or rheumatoid arthritis, wherein the medicament comprises a combination composition having approximately 125 mg to approximately 150 mg ibuprofen and approximately 475 mg to approximately 500 mg paracetamol.... Agent:

20110166235 - Viscoelastic system for drift reduction: The invention relates to a viscoelastic system for drift reduction for pesticidal formulations, and the use thereof, wherein said formulation comprising at least one nitrogen-based cationic surfactant and at least one pesticide, wherein said pesticide contains at least one acid functional group associating with said cationic surfactant thereby forming a... Agent: Akzo Nobel N.v.

20110166236 - Cleaning composition: A cleaning and disinfecting composition comprises a long-chain alkyl polyamine, such as dodecyl dipropylene triamine; a long-chain quaternary ammonium salt, such as N,N-didecyl-N,N-dimethylammonium chloride; and a metal carbonate salt, such as potassium carbonate, all in aqueous solution. A sequestering agent, a long-chain alkyl polyethoxylate, an alkanolamine and an anti-corrosive agent... Agent: Amity Limited

20110166237 - Process for the synthesis of arformoterol: The present invention provides a process for preparing a compound of formula (VI) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no... Agent: Cipla Limited

20110166238 - Cobbs company aftershave gel for men & women: Cobbs Company Aftershave Gel is a cosmetic product designed to moisturize and maintain healthy looking skin. Cobbs Company Aftershave Gel can be applied to the skin area after shaving. Cobbs Company Aftershave Gel contains water, white petroleum jelly, and isopropyl alcohol. These three ingredients should only be mixed, sold, and... Agent:

20110166239 - 2,3,3-trimethylcyclopent-3-enecarbaldehyde derivatives useful as odorants: b

20110166240 - Ph modulated films for delivery of actives: The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous... Agent: Monosol Rx, LLC

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.20276 seconds

PATENT INFO